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Alzheimer’s Disease is a neurodegenerative condition with progressively worsening 
memory and cognitive function, which ultimately results in death. The two major 
neuropathological hallmarks of AD are extracellular amyloid-beta (Aβ) plaques and 
intracellular neurofibrillary tau tangles (NFTs). Other pathways and neuronal 
mechanisms are also likely to be affected as AD is a complex disease resulting from 
anomalies in components of different pathways.  
Currently, apart from a few FDA approved drugs which serve to delay symptom 
progression through slowing neurotransmitter breakdown (Cholinesterase inhibitors) 
and cell damage (NMDA-receptor antagonist), no effective treatment of the underlying 
causes of AD is available. One of the hypothesised underlying cause of AD is the 
formation of extracellular Aβ plaques. Current work in the Neural Development and 
Disease (NDD) lab have researched viral-mediated gene therapy as a means to 
introduce a neuroprotective secreted amyloid precursor protein α (sAPPα) gene 
intracranially.  
This project’s primary aim was optimising and comparing the spread between lentiviral 
(LV) and adeno-associated viral (AAV) vectors; along with the effects of systemically 
delivering an osmotic agent, mannitol. Viral spread would be determined by the use of 
a GFP reporter gene, where expression indicated transduction and extent of viral 
spread. This project has showed a significant improvement in transduction efficiency 
when using an AAV vector to deliver a reporter gene. It efficiently achieved widespread 
transduction of the CNS from a unilateral injection at the hippocampus. However, while 
LV had a limited spread in comparison to AAV9, it would be useful for targeted delivery 
of treatment. Mannitol did not produce any significant effect on vector spread.  
The secondary aim was to create a plasmid to visualise secretion of sAPPα from virally 
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transduced cells. Once packaged into a lentiviral vector, the plasmid was shown to 
successfully transduce primary neurons in vitro, but expression of reporter genes were 





Chapter 1: Introduction  
1.1 Alzheimer’s Disease & Dementia  
1.1.1 Epidemiology and statistics  
Alzheimer’s Disease (AD) is an (as-yet) incurable neurodegenerative condition. AD is 
the most common form of dementia, thought to be responsible for 60-80% of all cases 
of dementia with over 48,000 (1.1%) of the population in New Zealand affected 
(Economics, 2011), and 36 million affected globally (Prince et al., 2014). Furthermore, 
about 40% of AD cases are thought to go undiagnosed or unreported, suggesting that 
numbers could be even higher (Prince et al., 2011).  
AD is a disease which affects the elderly, with most diagnoses of AD (96%) at age 65 
and above (Brookmeyer et al., 1998; Hebert et al., 2013). AD prevalence is expected 
to increase, a consequence of the aging population and projections have numbers in 
NZ expected to triple between the years 2011 to 2050 (Economics, 2011). Only 4% of 
AD patients are younger than 65, suffering from the much rarer early-onset AD (Hutton 
et al., 1996; Harvey et al., 2003). The incidence of AD rises significantly with age, with 
risk of developing AD doubling every 5 years after the age of 65; nearly half of the 
over-85 year old population will have developed AD (Prince et al., 2014).  
AD has a typical progression of symptoms; onset is typically characterised by short 
term memory loss (or an inability to form new memories), cognitive decline and 
behaviour/personality changes with later stages of basic body function impairments 
and death.  
In latter stages of AD, sufferers are no longer able to cope unaided, necessitating the 
need for caregivers to offer almost round-the-clock care. While this may come in the 
form of professional care, more often than not, family members may also give up time 
and income to provide some or all of the long-term personal care needed. This long-
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term care, professional or familial, is a great financial burden on society; estimated to 
cost over US$600 billion worldwide. The smallest contributions towards this societal 
cost comes from direct medical care; while the greatest contributor is made up of long-
term care and is especially pre-dominated by unpaid care provided by family 
(Alzheimer's Association, 2013).  
Due to the rising prevalence of AD and its resultant rising costs, it is vital to develop 
novel and effective treatment for AD. Strategies which can target, prevent and/or 
rescue the fundamental causes, rather than treating the symptoms alone will be the 
most desirable. The challenges are the unknown mechanisms or molecular triggers 
which cause disease development and the cause-and-effect sequence of brain 
anomalies observed in AD patients.  
 
1.1.2 Neuropathology of Alzheimer’s  
The biological and structural changes in a healthy ageing brain is vastly different from 
an AD affected brain. The normal process of ageing produces regional reduction in 
volume (Raz et al., 2005); this shrinkage has differential region-specific rates. Minimal 
change was observed in the entorhinal and visual cortices. Substantial shrinkage was 
observed in the cerebellum, hippocampus and association cortices; where rate of 
shrinkage in the cerebellum and hippocampus increased with age.  
In contrast, the entorhinal cortex is one of the first regions shown to be affected in 
early/mild AD (Braak et al., 1993; Du et al., 2001), and shrinkage has been shown to 
be a predictor of memory decline (Raz & Rodrigue, 2006). Hippocampal volume 
reduction was shown to correlate with severity of cognitive impairment from normal, 
mild cognitive impairment and AD affected individuals (Pennanen et al., 2004). The 
same paper corroborated that entorhinal cortex atrophy precedes atrophy of the 
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hippocampus in AD individuals. Brain atrophy is simply one of the features in AD 
affected brains; however it is not a defining characteristic as distinguishing between 
normal age-related and AD brain atrophy is difficult.  
Diagnosis of AD is made through symptoms and cognitive tests; symptoms observed 
include: memory loss and worsening cognitive function; such as aphasia, object 
recognition, motor function and decision making (Prince et al., 2014). Further tests can 
be conducted to reject symptom-causing diseases. Research and clinical diagnosis 
employ many tests to assess cognitive impairment; one of which is the AD 
Assessment Scale-Cognitive Subscale (ADAS-Cog) (Cano et al., 2010). Typically an 
assessment is carried out with multiple other tests, such as the Clinical Dementia 
Rating (CDR) (Hughes et al., 1982; Tan, Strauss & Sherman, 2011) or Mini-Mental 
State Examination (MMSE) (Cockrell & Folstein, 2002). Utilisation of multiple tests will 
be useful in tracking changes from normal ageing to mild cognitive impairment (MCI) 
to AD. It is important to note the difference between MCI and early/mild AD as MCI 
may not progress into AD, while early/mild AD will almost certainly progress.  
Improved diagnostic accuracy is possible with the use of scans like magnetic 
resonance imaging (MRI) or positron emission tomography (PET) (McGeer et al., 
1984; Albert et al., 2011); and potentially, biomarker testing (Humpel, 2011; Mapstone 
et al., 2014). But at the moment, confirmation of the diagnosis can only be made by 
post-mortem analysis of brain tissue. Primary hallmarks of AD that are looked for in 
brain tissue are neurofibrillary tangles and neuritic plaques (Wilcock & Esiri, 1982; 
Tiraboschi et al., 2004; Braskie et al., 2010).  
They were first characterised by A. Alzheimer in a case of “pre-senile dementia” 
(Alzheimer, 1907) and named Alzheimer’s Disease by E. Krapaelin in 1910 (Berrios, 
1990). The accumulation of neuritic plaques and neurofibrillary tangles are noticeably 
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greater in AD sufferers than healthy aging individuals (Price et al., 1991).  
The intracellular NFTs are made of hyperphosphorylated tau protein which aggregate 
to form insoluble tangles. NFTs alone are not diagnostic of AD as they are found in 
other disease related tauopathies and normal ageing (primary age-related tauopathy 
(PART); Crary et al., 2014). NFTs are observed as another age-related change to 
brain morphology. However while the density of NFTs may increase with age in a 
healthy individual, unlike an AD individual, they do not begin localising in specific 
regions and Aβ plaques are not a common feature seen across normal ageing brains 
(Price et al., 1991).  
Thus in combination with other pathologies, Aβ plaque presence and load are a unique 
characteristic for AD diagnostic pathology. In healthy, unaffected individuals, Aβ is 
simultaneously formed and degraded which makes their accumulation an anomaly. 
The idea that Aβ plaques are the underlying cause of AD is known as the amyloid 
hypothesis. The presence of Aβ plaque in AD pathology will be discussed further 
(section 1.2.1) and is the current focus of the NDD lab’s efforts in AD treatment.  
 
1.1.3 Affected neuroanatomy in Alzheimer’s  
It was previously mentioned that cortical regions, the hippocampus and entorhinal 
cortex suffer from atrophy in individuals with AD. The entorhinal cortex has been 
shown to be one of the first region of the brain to be affected in early/mild-AD 
individuals (Du et al., 2001; Khan et al. 2014).  
The hippocampus, which is the region of the brain responsible for learning, memory 
and spatial navigation (White & Gaskin, 2006; Winocur et al., 2006); is one of the major 
regions of the brain to suffer atrophy in AD (Pennanen et al., 2004). Brains from AD 
individuals show increased region-specific localisation of NFTs; especially in the 
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hippocampus, with tangles appearing within the cornus ammonis region 1 (CA1) in 
older individuals (Price et al., 1991; Rodriguez et al., 2013; Neuman et al., 2015). This 
correlates with early symptoms of learning and short-term memory failure. The CA1 
and entorhinal cortex have a similar and related pathology in AD due to the shared 
network that they are components of.  
Research into episodic memory has revealed that memory is primarily stored in the 
neocortex; with consolidation through interactions with the hippocampus. 
Hippocampus and neocortex interactions are largely mediated by the entorhinal cortex 
(Fyhn et al., 2004). The EC-hippocampus system processes multi-sensory information 
received by the association cortices in the formation of memory for storage (Burwell, 
2000; Suh et al., 2011). The inputs and outputs to and from the entorhinal cortex and 
hippocampus allow for retrograde transport of virally delivered transgene products 
along the axonal projections between regions.  
Unsurprisingly, this has made the hippocampus a well-studied region with regards to 
AD, especially in animal models. The hippocampus has been shown to exhibit discrete 
functional regions; the ventral hippocampus is implicated in anxiety-related behaviours 
while the dorsal hippocampus (of which the CA1 region is a part of) mediates memory 
and spatial memory (Strange et al., 2014). It is for these reasons that the CA1 region 
of the hippocampus was selected as a meaningful AD-related target site for viral vector 
delivery. This region of the hippocampus has been shown to be associated with 
learning and memory (Bartsch et al., 2011). Alterations in long-term potentiation (LTP) 
in this region resulted in impairments to spatial learning (Okada et al., 2003). While 
lesions to the CA1 and CA3 regions affect memory retrieval (Hasselmo, 2005; Ji and 




1.2 Risk factors and associated causes of Alzheimer’s  
AD does not have a single definitive cause, rather it is a result of a myriad of 
heterogeneous factors that form the disease symptoms known as Alzheimer’s 
Disease. It does, however, have a few known risk and association factors. Old age, as 
mentioned before, is the major risk factor of AD. Other epidemiological risk factors that 
are linked to AD are cerebrovascular diseases (Jellinger, 2002), hypertension (Skoog 
& Gustafson, 2006) and head injuries (Mayeux et al., 1995; Nicoll et al., 1995).  
In terms of causative factors, there are a number of proposed hypotheses such as the 
tau or cholinergic hypothesis. This project will focus on the amyloid hypothesis and 
how viral vector mediated gene therapy will seek to treat the formation of Aβ plaques.  
 
1.2.1 Amyloid Hypothesis  
The amyloid hypothesis proposes that the AD pathogenesis begins with accumulation 
of Aβ peptides which form neuritic plaques (Hardy & Higgins, 1992; Hardy, 2009; Sung 
et al., 2014) before symptom development and secondary pathologies (such as NFTs).  
MRI scans have shown that amyloid precursor protein (APP) expression within the 
entorhinal cortex drives tau spread and toxicity (Khan et al., 2014). Initiation of Aβ 
formation has been suggested to be due to cerebral capillary haemorrhaging (Stone, 
2008). The hypothesis proposed that a capillary haemorrhage provides an ischaemic 
condition which promotes Aβ formation and haemoglobin oligomerises Aβ into 
plaques. This is supported by the fact that cerebrovascular disease is a risk factor for 
AD (Esiri et al., 1999; Jellinger, 2002) and the elderly have weaker capillary beds which 
are more prone to rupture. Furthermore, it would explain Aβ deposition following 





Figure 1.1 – Processing of amyloid precursor protein by the amyloidogenic or non-
amyloidogenic pathway with α-, β- and γ-secretases  
Amyloid precursor protein (APP) can proceed down the amyloidogenic or non-amyloidogenic pathway 
by the initial cleavage of β- or α-secretase respectively. Subsequent cleavage by γ-secretase forms 
either the amyloid-β (responsible for neuritic plaques; under the amyloidogenic pathway) or 
neuroprotective sAPPα (under the non-amyloidogenic pathway).  
Picture reproduced with permission from Eva Babusikova, Andrea Evinova, Jozef Hatok, Dusan 
Dobrota and Jana Jurecekova (2013). Oxidative Changes and Possible Effects of Polymorphism of 
Antioxidant Enzymes in Neurodegenerative Disease, Dr. Uday Kishore (Ed.) 
 
Aβ is produced from the proteolytic pathway of the transmembrane amyloid precursor 
protein (APP). APP processing may proceed down either the amyloidogenic or non-
amyloidogenic pathways, where APP may be initially cleaved by either β- or α-
secretase, respectively. In the amyloidogenic pathway, APP is first cleaved with β-
secretase. This produces a soluble N-terminal APP fragment (sAPPβ) and a C-
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terminal fragment (β-CTF). The transmembrane β-CTF is further cleaved by γ-
secretase to produce the extracellular Aβ and APP intracellular domain (AICD).  
There are two main species of Aβ produced, Aβ40 and Aβ42, due to different cleavage 
sites of γ-secretase producing different lengths of Aβ. Aβ42 is the more toxic form; 
aggregating easily and making up the major component of neuritic plaques. The 
Aβ42/Aβ40 ratio is a potential biomarker for AD.  
Aβ was found to increase neuronal sensitivity to excitotoxicity and was neurotoxic in 
neuronal cultures (Hardy & Higgins, 1992). Aβ was found to be only neurotoxic to 
mature neurons; while having a neurotrophic effect (at low concentrations) to 
undifferentiated hippocampal neurons (Yankner et al., 1990). The neurotoxic 
mechanisms of Aβ in causing cell death have been suggested to be: interference with 
calcium ion homeostasis resulting in neuronal loss (Mark et al., 1995), endoplasmic 
reticulum (ER) stress, accumulation in autophagic vesicles resulting in lysosomal 
leakage (and subsequent cell death) and disruption of mitochondrial function to cause 
apoptosis (Umeda et al., 2011).  
In the non-amyloidogenic pathway, APP is initially cleaved by α-secretase in the 
middle of the Aβ region. This produces a larger N-terminal APP fragment (sAPPα) and 
a αCTF. αCTF is then cleaved by γ-secretase. The larger sAPPα has been found to 
have neurotrophic and neuroprotective properties (Turner et al., 2003; Turner et al., 
2007); being 100 times more effective than sAPPβ in conferring neuroprotection to 
hippocampal cells against excitotoxicity, Aβ neurotoxicity, and glucose deprivation 
(Furukawa et al., 1996).  
Aβ levels in the brain are maintained by a constant cycle of generation and clearance; 
an imbalance will result in accumulation and formation of neuritc plaques. Thus, 
sAPPα is a therapeutic of interest and past work in the NDD lab had used lentiviral-
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mediated delivery of a sAPPα transgene to both rescue and prevent AD symptoms.  
 
1.2.2 Genetic risks  
There are numerous AD associated genes which carry with them a small but 
nonetheless significant risk. Because Aβ formation is a major contributing factor to AD 
pathogenesis, the APP gene which expresses the precursor protein for Aβ is known 
to be directly linked to AD. There are three other genes linked to AD; Apolipoprotein E 
(APOE4 in particular), and Presenilin 1 and 2 (PSEN1 and PSEN2) (Tanzi & Bertram, 
2005).  
The APP gene is located on chromosome 21 and mutations within the Aβ region of 
the APP gene can result in hereditary susceptibility for AD; according to Tanzi and 
Bertram, 2005, there are 16 established mutations, most increasing the Aβ42/Aβ40 ratio 
and Aβ generation and aggregation. Three mutations at codon 717 of the APP gene 
cause familial AD (Hardy & Higgins, 1992), while another mutation of the 
transmembrane Aβ region resulted in an autosomal dominant inheritance of AD in 
family members (Murrell et al., 1991). Other familial AD have been reported with 
mutations found outside of the Aβ region which resulted in a rise in Aβ production 
(Citron et al., 1992). Furthermore, its increased expression from trisomy 21 has been 
linked as a likely cause of early-onset AD in individuals with Down Syndrome (Lott & 
Head, 2005; Shi et al., 2012).  
The ApoE4 allele is found on chromosome 19 and encodes the apolipoprotein E4 
variant; which has been linked to a number of diseases. In terms of its role in AD, the 
E4 isoform is linked to sporadic late-onset AD and thought to do so by tipping the Aβ 
balance by increasing aggregation and decreasing clearance.  
The PSEN1/2 genes are part of a family of transmembrane proteins which form a 
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complex with γ-secretase. PSEN1 is found on chromosome 14 while PSEN2 is found 
on chromosome 1. They are both strongly linked to early-onset familial AD (Wragg et 
al., 1996). According to the Alzheimer Disease & Frontotemporal Dementia Mutation 
Database (Cruts et al., 2012), there are 196 known mutations in PSEN1 and 25 in 
PSEN2. A large number of the mutations cause an increase in the Aβ42/Aβ40 ratio 
(Tanzi & Bertram, 2005).  
To illustrate the mechanisms of these genes, a double transgenic (tg) mouse was 
created which carried mutant APP and PSEN1 transgene (Holcomb et al., 1998). An 
APP mutant tg mouse had hippocampal and cortical extracellular Aβ deposites while 
the PSEN1 mutant tg mouse had increased levels of Aβ42. The double tg mice 
produced from crossing the two mutants developed AD-like pathology and Aβ plaques 
much earlier and is a better model for AD therapeutic research as it has an additional 
facet of the disease which can be tested at the same time. In this case, increased 
levels of Aβ42 and high levels of plaque formations.  
To summarise the significance of the amyloid hypothesis in AD pathogenesis; 
regardless of the mechanisms or pathways which result in the presence of neuritic 
plaques, the negative impact Aβ plaques have on the brain and cognitive function is 
undeniable (Selkoe, 2008). They can block cell-cell communication at synapses, 
resulting in impairments in learning and forming new memories and progressively, 
memory recall. Aβ contributes to cell death directly by inducing apoptosis and 
disrupting organelle function. Indirectly, Aβ may also activate an immune response to 
trigger inflammation and recruit immune cells which phagocytose non-functional cells, 
contributing to cell death. The resultant cell loss eliminates portions of signalling and 





1.3 Gene therapy  
Gene therapy was developed as a technology to introduce a functional copy of a gene 
to specific sites as a therapeutic for genetic diseases (Rogers, 1970; Friedmann & 
Roblin, 1972). However, delivery of a gene into sites of interest requires a vector to 
carry the DNA and facilitate entry.  
Gene therapy has the advantage of reducing (or in some cases, eliminating the need 
for multiple and sustained administration of the therapeutic. This is because it has 
been shown that there can be robust transgene expression up to 2 years after viral 
vector introduction (Tan, unpublished PhD research).  
The vector types used are classed into methods which use viral vectors or non-viral 
methods. Examples of non-viral vectors include oligonucleotides, lipoplexes and 
inorganic nanoparticles.  
 
1.3.1 Viral vectors  
Treatment with viral mediated gene therapy utilises the inherent ‘invasive’ properties 
of viruses as a delivery mechanism; where viruses bind and introduce a therapeutic 
transgene instead of their genomes into host cells, transgene expression would rescue 
or prevent the effects of a disease causing mutant.  
Following identification of a potential therapeutic gene, the wildtype viral genome is 
modified to create a construct with 1) a promoter to allow either constitutive or specific 
expression of 2) the therapeutic gene and/or 3) a reporter gene to allow for its detection 
and selection. To create the vector, the construct is then packaged into its viral particle 
before being introduced in vitro or in vivo.  
Conceptually straightforward, it proved more challenging in practice; with selection of 
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the viral vector having to meet certain requirements before use; 1) modification to 
remove pathogenicity: usually by the deletion of replication and/or packaging genes 
(which serves a two-fold purpose of increasing transgene capacity), 2) tissue 
specificity: by virus choice and/or pseudotyping, 3) identification: insertion of a reporter 
gene such as antibiotic resistance.  
Viral vectors commonly modified for use are lentivirus (LV) (Lundberg et al., 2008; 
Matrai et al., 2010) and adeno-associated virus (AAV) vectors (Warrington & Herzog, 
2006).  
 
1.3.2 Lentivirus vs. Adeno-associated virus  
LV are retroviruses containing single-stranded, positive sense RNA, which have the 
ability to transduce both dividing and non-dividing cells. They have a relatively large 
genome capacity of approximately 9-10 kb, and elicit a minimal immune response 
which makes them ideal as a vector choice This makes them a useful choice for gene 
therapy within the central nervous system (CNS), especially for their ability to 
transduce non-dividing cells such as neurons. Following cell entry, the LV genome is 
reverse transcribed and integrated randomly into the host genome, resulting in long 
term expression; even after cell replication, expression is sustained in daughter cells. 
The unpredictable integration was shown to have a tendency to cause mutagenesis 
at a low rate (Montini et al., 2006).  
AAV are parvovirus containing single-stranded DNA (ssDNA), also with the ability to 
transduce both dividing and non-dividing cells (Weinberg et al., 2012). AAV are also 
non-pathogenic and not known to be disease causing in humans, making them 
another suitable vector choice. Unlike LV vectors, AAV most often integrate 
predictably into the host cell genome; at human chromosome 19 (Kotin et al., 1990; 
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Surosky et al., 1997). However, due to a much smaller genome capacity; of 
approximately 4.7 kb, the genes responsible for this capability have typically been 
removed in AAV vectors to increase their transgene capacity. This causes either 
random integration or persistence in an episomal state (Flotte & Carter, 1995). 
However, episomal DNA is lost in subsequent generations of daughter cells as it is not 
replicated along with host DNA.  
 
1.4 Enhancing transduction efficiency  
Initially, most gene therapy trials had begun with the aim to treat monogenetic 
diseases such as cystic fibrosis (Hyde et al., 1993), haemophilia (Kay et al., 1992) and 
muscular dystrophy (Cox et al., 1993). However, there was much difficulty in achieving 
tissue specific targeting along with high levels of transduction efficiencies. Due to 
modifications to the wildtype viral genome, most vectors are rendered replication-
deficient, therefore each vector introduced is required to be as “efficient” as possible 
at attaching and facilitating entry into a cell.  
Gene therapy within the central nervous system (CNS) presents additional unique 
challenges such as; mature non-dividing cells, heterogeneous cell types and selective 
access (Costantini et al., 1999). The CNS is highly selective about macromolecule 
entry; which means novel methods to facilitate entry into the brain. Direct intracranial 
injections are more invasive but remove the need to bypass the blood-brain barrier; 
which is the main selective barrier that needs to be bypassed by most other routes of 
administration. Intracranial delivery of viral vectors still have certain hurdles such as 
the densely packed nature of the neuronal cells which prevent spread from the site of 




1.4.1 Serotyping vs. Pseudotyping  
Methods which were previously examined to improve the transduction efficiencies of 
AAV looked at the various serotypes and their natural tropism range; where tissue 
specificity was determined by capsid serotype (Grieger & Samulski, 2005; Zincarelli et 
al., 2008). AAV serotypes are assigned based on the different capsid proteins and the 
resulting affinity conferred to distinct host or tissue type receptors which serves to 
facilitate entry via receptor-mediated endocytosis (Yan et al., 2002).  
The serotype used in this project; AAV9, has been shown to exhibit natural tropism 
towards the CNS and global bio-distribution (when introduced intravenously), it also 
shows rapid-onset and high expression levels (Zincarelli et al., 2008).  
Altering the tropism of LV vectors can also be accomplished by pseudotyping, which 
is the replacement of natural viral envelope glycoproteins with foreign glycoproteins to 
produce a pseudotyped viral vector, with altered tropism. The viral vector then attains 
the host tropism of the virus from which the glycoprotein was originally derived, due to 
gaining an increased binding affinity (Cronin et al., 2006).  
Prior work in the NDD lab has worked on pseudotyping surface glycoproteins on virus 
particles to improve transduction efficiencies. A glycoprotein used in the NDD lab takes 
advantage of the neural tropism of the family of rabies virus. The vesicular stomatitis 
virus glycoprotein G (VSV-G) is used due to its stable pseudotype and wide tropism 
of all cell types (Trono, 2000; Mazarakis et al., 2001).  
 
1.4.2 Osmotic agents (Mannitol)  
Apart from modifying the viral vectors, the tightly regulated and highly selective 
environment of the CNS, and brain in particular, can be subtly altered to assist with 
increasing distribution of viral vectors (or therapeutic macromolecules) throughout the 
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CNS. The ever-present difficulty of macromolecule delivery into the brain is the blood-
brain barrier (BBB) which is a neuroprotective separation preventing diffusion between 
the blood and brain extracellular fluid; however, the BBB is only a problem when 
introducing viruses systemically with the goal of entry into the brain. However, with 
intracranial delivery of viral vectors, the difficulty is no longer the inability to cross the 
BBB to enter the brain but tightly packed neurons and glial cells which prevents the 
spread of viral vectors from a localised point of injection.  
Osmotic agents are commonly used as a means of relieving intracranial pressure by 
decreasing extracellular fluid (ECF) volume (Mohanty et al., 2011). The osmotic agent, 
mannitol, is a commonly used BBB disruptor to achieve improved diffusion within the 
brain. Mannitol generates a positive osmotic pressure within neural cells which causes 
water to exit the cells along the osmotic gradient (Pardridge, 2001). Consequently, the 
cells shrink and move apart. This provides greater extracellular access and results in 
greater spread of macromolecules, such as viral vectors, from the point of introduction. 
The effect of mannitol has been found to peak approximately 4-5 hours post-
administration and return to baseline levels by 24 hours post-administration (Burger et 
al., 2004) 
Current research has used mannitol to enhance brain microcirculation but an explicit 
examination and determination of an optimised concentration and route of 
administration has not been conducted. However, the general consensus has reported 
improved transduction efficiency resulting from the use of mannitol treatment (Ghodsi 
et al., 1999; Mastakov et al., 2001; Carty et al., 2010).  
The concentrations of mannitol used varied; from 6.7% to 25% (Burger et al., 2005; 
Fu et al., 2003), along with the volume delivered and the rate at which that volume 
was administered. Differing concentrations of mannitol was trialled by Fu et al., 2003, 
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with 12.5% mannitol having similar results to negative controls; with observably higher 
transduction efficiencies with 25% mannitol.  
This project will use 25% w/v mannitol delivered systemically to observe the effect it 
has on viral vector spread  
 
1.5 Visualising secretion of sAPPα from transduced cells  
Previous studies in the Neural Development and Disease lab have utilised a LV to 
deliver sAPPα with a separate GFP in preventative and rescue studies. LV injection 
occurred pre- and post-symptom manifestation before conducting behavioural and 
post-mortem studies. The post-mortem observations were only able to observe the 
regions of virus spread through the GFP expressing transduced cells. But it was 
unknown where the secreted therapeutic sAPPα had travelled to. This was important 
to know as AD results in various regions of the brain being affected and expression is 
secondary to delivery of the therapeutic to regions of the brain where it was needed.  
The design of a plasmid containing a GFP-sAPPα-T2A-mCherry transgene enabled 
transduced cells to be observed with the mCherry reporter while cleavage at the T2A 
peptide allowed GFP-tagged sAPPα to be secreted and its extracellular spread can 






This project has 2 overall aims regarding viralvector mediated gene therapy for 
Alzheimer’s Disease;  
1) Primarily we are comparing the spread and distribution of lentivirus to adeno-
associated virus mediated transduction of neuronal cells; main points of 
comparison are physical distance of spread and regions of reporter gene 
expression. We will also look how an osmotic agent, mannitol, is able to 
increase the spread of viral vector delivery through its hyperosmotic action.  
2) Secondary to the first aim, design of a plasmid to visualise secretion of the 
therapeutic secreted amyloid precursor protein α. This is achieved with a 
sAPPα molecule with a GFP reporter tag and a mCherry reporter gene, oth 






Chapter 2: Materials and methods  
Wildtype mice (strain C57BL/6), aged 3 to 4 months old, were injected unilaterally into 
the CA1 region of the hippocampus in the left hemisphere. One microlitre of either the 
lentivirus (LV) or adeno-associated virus serotype 9 (AAV9) was injected at an infusion 
rate of 150 nL/min. The viral vectors expressed a green fluorescent protein (GFP) 
reporter gene. The needle was left in place before being drawn up slowly to prevent 
backflow of the viral vectors. Incubation times varied from 7, 14 to 28 days; however, 
treatment groups used in subsequent comparison were all incubated for 28 days.  
To compare the use of different viral vectors and the effect of mannitol, the mice were 
perfused at the end of the incubation period. The brains were fixed, cryoprotected and 
frozen prior to sectioning. Sections were imaged for GFP expression and mapping 
using fluorescent microscopy. The area of GFP expression was quantified to 
determine the spread and transport of viral vectors from the site of injection. The total 
distance of spread from anterior to posterior of the brain and distribution of GFP 
expression was calculated to compare the effect of using either LV or AAV9 vectors 
along with the effects of using the osmotic agent, mannitol.  
Immunohistochemistry was also carried out on sections of tissue to determine cell 
types that were transduced. NeuN antibodies were used to determine if neurons were 
transduced while GFAP antibodies were used to stain for astrocytes (indicating an 
immune response to viral vector treatment). Anti-GFP staining was used in some 
cases to enhance weak GFP signal (or in some cases, confirm the absence of GFP) 
in some tissue.  
To visualise the secretion of secreted amyloid precursor protein α (sAPPα) from 
lentiviral transduced neurons, a plasmid was designed to express a GFP-tagged 
sAPPα molecule and mCherry as a fused protein, bisected by a T2A peptide. 
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Expression was controlled by a synapsin promoter.  
Upon cleavage at the T2A peptide, the mCherry reporter molecule would remain in the 
transduced neurons while the sAPPα molecule would be secreted extracellularly. The 
GFP tag would enable visualisation of sAPPα (green) while differentiating from 
transduced neurons (red).  
 
2.1 Plasmid design and cloning of pCDH-pSyn-SP-GFP-sAPPα-T2A-mCherry 
A plasmid was designed to contain a GFP-sAPPα-T2A-mCherry sequence which 
would allow for visualising sAPPα via a GFP tag while differentiating from transduced 
neurons with mCherry. The plasmid was created by linearising a pre-existing 9615 
base-pair (bp) plasmid vector pCDH-pSyn-SP-GFP-sAPPα (generated by Dr Lucia 
Schweitzer using a sAPPα clone from Prof Warren Tate) by SalI restriction digest. The 
T2A-mCherry insert was amplified with In-Fusion® primers from a plasmid containing 
the region of interest [pCDH-pSyn ffloxed Kozak-T2A-mCherry], to produce an 
approximately 813 bp sequence with complementary 15-20 bp overhangs to the vector 
plasmid. An In-Fusion® reaction was carried out to ligate insert fragment to vector. 




Figure 2.1 – pCDH-pSyn-SP-GFP-sAPPα-T2A-mCherry plasmid  
The plasmid shown has a GFP reporter tag (green), sAPPα gene (blue), T2A (purple triangle), mCherry 
reporter gene (red) and AmpR selection gene (yellow). Figure created using Geneious (version 8.1).  
 
Competent cells were transformed and screened with colony PCR for positive 
colonies. Likely positive colonies were crude-mini-prepped for DNA isolation and 
sequencing. A sequence which was positively aligned with the desired insert present 




2.1.1 In-Fusion® primer design  
Primers used for amplifying and cloning of the T2A-mCherry sequence were designed 
with the aid of Geneious. The primers were designed to allow for an in-frame insertion 
of the T2A-mCherry sequence after the sAPPα gene in the vector plasmid, while 
removing the STOP codon to allow for expression under the same Synapsin promoter.  
The forward primer served to produce a complementary overhang with the 3’ end of 
sAPPα while removing its STOP codon. The reverse primer produced a 
complementary overhang with the plasmid vector while removing the SalI restriction 
cut site. These primers are shown in Table 1.1.  
Primer  Sequence (5’ to 3’)  
618 InF mCherry rev GAGGTTGATTGTCGACTTACTTGTACAGCTCGTCCAT 
619 InF sAPPα T2A 
fwd  
AAGTTCATCATCAAAAAGTCGAGGGCAGAGGAAGT 
Table 2.1 – In-Fusion® primer sequences  
Green: vector-specific overhang; Red: complementary mCherry sequence; Yellow: complementary T2A 
sequence.  
 
The expected insert from PCR amplification using the designed In-Fusion® primers is 
shown in Figure 2.2 below.  
 
Figure 2.2 – T2A-mCherry sequence  
The expected insert fragment (777 bp; 813 bp when including overhangs) from amplification using In-
Fusion® primers (beige) with vector-specific complementary overhangs (green) flanking T2A (yellow) 




2.1.2 Amplification of insert using In-Fusion® primers  
PCR was carried out using brand new aliquots of all reagents (due to prior 
unsuccessful attempts leading to a conclusion of possible contamination in the PCR 
reagents). Each 50 μL reaction contained 5 μL of 10X buffer, 1.5 μL of 50 mM MgCl2, 
1 μl of Roche PCR Grade Nucleotide Mix (10mM each dNTP), 1μL of each forward 
and reverse primers (10 mM), 0.5 μL of Platinum Taq DNA Polymerase (Invitrogen, 
NZ) and either 30, 50, 100 or 300 ng of plasmid DNA; with the remaining volume 
consisting of sterile dH2O. Each reaction of different DNA concentrations was 
prepared and carried out in duplicate, for a total of 8 reactions. An additional 2 
reactions containing only 100 ng of plasmid DNA without primers were included as 
negative controls. PCR amplification was carried out in a BioRad C1000 thermal 
cycler.  
Primer  PCR parameters  Amplicon size  
618 InF mCherry rev  
619 InF sAPPα T2A fwd 
1. 95 °C – 3 minutes  
2. 95 °C – 30 seconds  
3. 55 °C – 1 minute  
4. 72 °C – 1 minute  
5. 35 cycles of 2-4  
6. 72 °C – 5 minutes  
813 bp  
Table 2.2 – PCR parameters for T2A-mCherry amplification using In-Fusion® primers  
 
2.1.3 Agarose gel electrophoresis  
All gel electrophoresis (unless otherwise stated) were carried out in a Thermo 
Scientific Easycast B1 tank with 50 mL of 1% UltraPure Agarose (Invitrogen) gels with 
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5 μL of 10 mg/mL ethidium bromide (Invitrogen NZ; 10488-085) immersed in 1x TAE 
buffer also with 5 μL of ethidium bromide pipetted into the gel tank at the positive 
terminal and electrophoresed using a BioRad PowerPac HC.  
5 μL of each of the 8 experimental reactions and both negative controls (2.1.2) was 
mixed with 1 μL of loading dye before loading into wells before running out on a 1% 
agarose gel for 1 hour at 100 V (or until the loading dye had run at least halfway down 
the gel). TrackIt 1 kb Plus DNA Ladder (Invitrogen NZ; 10488-085) was used to 
determine the amplified fragment size. The gel was imaged and photographed on a 
BioRad Gel Doc imager using UV transillumination under the appropriate settings.  
 
2.1.4 Purification of PCR product  
Of the 8 experimental reactions, PCR purification was carried out on the sample which 
began with 300 ng of plasmid DNA. PCR purification was carried out according to 
instructions in Nucleospin Gel & PCR clean-up kit (Macherey-Nagel), section “5.1 PCR 
clean-up”.  
For every 1 volume of sample, 2 volumes of Buffer NTI was added. The whole sample 
was then loaded onto a Nucleospin Gel and PCR Clean-up Column in a collection tube 
and centrifuged at 11,000 x g 30 seconds. The flow through was discarded. The 
membrane was washed by adding 700μL Buffer NT3 and centrifuged at 11,000 x g for 
30 seconds. The flow through was discarded again and the wash step repeated.  
The flow through was discarded and the membrane dried of Buffer NT3 with an 
additional minute of centrifugation at 11,000 x g. The spin column was placed in a new 
collection tube. DNA was eluted by adding 15 μL Buffer NE, incubating at room 
temperature for 1 minute and centrifuging at 11,000 x g for 1 minute. Eluted DNA was 
stored at -20 °C. 
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The concentration of DNA was measured using a Nanodrop Technologies 
spectrophoto-meter, which was blanked using TE buffer.  
 
2.1.5 Gel extraction and purification  
For gel extraction and purification of PCR product, each remaining reaction (~45 μL) 
of the 30, 50 and 100 ng starting plasmid DNA concentration was mixed with 6 μL of 
loading dye and 50 μL of the mixture was electrophoresed on a 1% agarose gel for 1 
hour at 100 V. To reduce prolonged UV damage to the DNA, the bands of amplified 
inserts were visualised using UV light on the Polaroid MP4 land camera and cut out 
using a sterile scalpel and placed into 1.5 mL microcentrifuge tubes.  
The gel extraction protocol was carried out according to instructions for DNA extraction 
from agarose gels in Nucleospin Gel & PCR clean-up kit (Macherey-Nagel).  
Following gel excision, the gel fragment was solubilised. For every 100 mg of agarose 
gel, 200 μL of Buffer NTI was added and the samples incubated at 50 °C, vortexing 
briefly every 2 minutes until melted. Subsequent steps are identical to those listed in 
(2.1.4) for purification of PCR product.  
 
2.1.6 Restriction digest of vector plasmid  
Restriction digest was used to linearise the vector plasmid. Restriction digest was 
carried out on pCDH-pSyn-SP-GFP-sAPPα using the restriction enzyme SalI which 
cut the vector plasmid at the 3’ end of sAPPα.  
A 30 μL restriction digest consisted of 3 μL of SalI buffer, 1 μL of SalI restriction 
enzyme and 1 μg of vector plasmid DNA; with the remaining volume made up with 




2.1.7 In-Fusion® reaction  
The In-Fusion® reaction was carried out according to instructions in the In-Fusion® 
HD Cloning Kit User Manual (Clontech® Laboratories, Inc), Section VI.B: In-Fusion® 
Cloning Procedures for Spin-column purified PCR fragment.  
All reactions were made up to a total volume of 10 μL. The cloning reaction contained 
approximately 50 ng of purified insert DNA and 200 ng of linearised vector DNA, and 
2 μL of 5x In-Fusion® HD Enzyme Premix (Clontech®); with the remaining volume 
made up with sterile dH2O. The negative control consisted of no purified insert DNA, 
1 μL of linearised vector DNA and 2 μL of 5x In-Fusion® HD Enzyme Premix 
(Clontech®); with the remaining volume made up with sterile dH2O. The positive 
control consisted of 2 μL of 2 kb control insert (Clontech®), 1 μL of pUC19 control 
vector (Clontech®) and 2 μL of 5x In-Fusion® HD Enzyme Premix (Clontech®); with 
the remaining volume made up with sterile dH2O. All samples were incubated at 50 °C 
for 15 minutes for the In-Fusion® reaction to occur. All reactions were stored at -20 °C 
until used for transformation of competent cells.  
 
2.2 Transformation of competent E.coli 
All E.coli use was approved by the Environmental Risk Management Authority 
(ERMA), now the Environmental Protection Agency (EPA) and is carried out under 
approval number GMD002848.  
PC1 conditions were observed while conducting transformation of genetically modified 
E.coli. Stbl3 competent E.coli cells were used for transforming with the plasmid 
construct due to high transformation efficiency and high DNA yields.  
The Stbl3 cells were thawed on ice and 2.5 μL of both the In-Fusion® only and In-
Fusion® + SalI reactions were added to the competent cells. For controls, 2.5 μL of 
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the In-Fusion® positive and negative controls were also added to competent cells. 
Cells were incubated on ice for 30 minutes prior to heat shocking at 42 °C in a 
waterbath for 45 seconds for transformation to occur before returning to ice for 2 
minutes. 250 μL of S.O.C media (Invitrogen) was added to each sample and incubated 
at 37 °C for an hour in an Innova 4300 Incubator Shaker (New Brunswick Scientific) 
shaker at approximately 225 rpm. All samples were spun down using a Thermo 
Scientific Heraeus Pico17 centrifuge at 6000 rpm for 5 minutes to concentrate cells. 
The supernatant was removed and the pellet resuspended in 100 μL of S.O.C media. 
All 100 μL of both experimental and both (positive and negative) controls were spread 
onto separate Lennox L agar (LB agar) plates (Invitrogen) containing 100 μg/mL of 
ampicillin (Sigma Aldrich) using ethanol and flame sterilised glass Pasteur pipettes 
(Volac). Plates were incubated agar-side up at 37 °C overnight.  
 
2.3 Identifying positive transformants and isolation of plasmid DNA  
2.3.1 Colony PCR  
Screening for positive colonies of transformants containing the plasmid construct was 
achieved by performing colony PCR. This process can be a simple way of determining 
the presence of a desired insert DNA sequence within a plasmid construct. The 
presence of insert DNA is detected either using primers which will amplify the insert 
DNA to determine its presence or using primers flanking the insert region to determine 
its presence from the resulting fragment size.  
In this case, a combination of both primer choices was used. A mCherry 3’ forward 




Primer  Sequence (5’ to 3’)  
318 mCherry 3’ seq fwd   CCCGGCGCCTACAACGTCAA 
379 WPRE rev Nterm  GCAGCGTATCCACATAGCG 
Table 2.3 – Colony PCR primer sequences  
 
Each 25 μL reaction was prepared with 2.5 μL of Taq 10X buffer (brand and details), 
0.5 μL of dNTPs (10 mM each), 1 μL of forward primer (10 pmol), 1 μL of reverse 
primer (10 pmol), 0.2 μL of Taq polymerase and 19.8 μL of dH2O. Each 25 μL is 
aliquoted into separate 0.2 mL PCR strip tubes (Axygen). In-Fusion and In-Fusion + 
SalI colonies are picked off plates with a pipette tip and struck onto a new agar plate 
before dipping into the PCR strip tube, turned to mix and then discarded. PCR 
amplification was carried out in a BioRad C1000 thermal cycler. 
Primer  PCR parameters  Amplicon size  
318 mCherry 3’ seq fwd  
379 WPRE rev Nterm  
1. 95°C – 3 minutes  
2. 95°C – 30 seconds  
3. 60°C – 30 seconds  
4. 72°C – 1 minute  
5. 35 cycles of 2-4  
6. 72°C – 5 minutes  
221 bp  
Table 2.4 – PCR parameters for colony PCR of transformants  
 
Successful amplification by both primers will produce an approximately 200bp 





Figure 2.3 – Colony PCR product  
The selected primers (dark and light green) will amplify through the 3’ end of the inserted mCherry 
sequence into the vector plasmid if the In-Fusion® reaction was successful.  
 
PCR products are run on an agarose gel (2.1.3) to determine if the insert DNA has 
been successfully introduced into the vector plasmid by the presence of a band of the 
desired size.  
 
2.3.2 Mini-prep isolation of plasmid DNA  
Positive colonies which produce the expected PCR fragment will be inoculated in 5 
mL of Luria broth (LB; Sigma Aldrich) containing 100 μg/μL ampicillin. All were 
incubated at 37 °C overnight to grow; along with an uninoculated control. Following 
the overnight incubation, the tubes were checked for signs of growth (cloudy LB broth) 
as well as ensuring that the uninoculated control was free of contamination (clear 
broth).  
1.5 mL microcentrifuge tubes were than filled with the broth of overnight growth and 
centrifuged at 13000 rpm for 1 minute. The supernatant was discarded and the pellet 
resuspended in 300 μL of Qiagen buffer P1 (Resuspension Buffer) by vortexing. 300 
μL of Qiagen buffer P2 was added and vortexed to lyse the bacteria before adding 300 
μL of Qiagen buffer P3 (neutralisation buffer) and vortexed again. The entire mixture 
was centrifuged at 13000 rpm for 10 minutes. The supernatant (with plasmid DNA) 
was transferred to a fresh microcentrifuge tube while avoiding the pellet. 300 μL of 
Phenol:Chloroform:Isoamyl Alcohol (24:24:1) (Sigma Aldrich) was added and 
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vortexed before being centrifuged at 13000 rpm for 10 minutes. The top aqueous 
phase (with plasmid DNA) was again transferred to a fresh microcentrifuge tube and 
500 μL of room temperature isopropanol was added and vortexed for DNA 
precipitation; and centrifuged at 13000 rpm for 10 minutes to pellet the DNA. The 
supernatant was discarded and the DNA pellet was washed with 500 μL of 70% 
ethanol and centrifuged at 13000 rpm for 2 minutes. The ethanol was discarded and 
the DNA pellet air dried.  
Once dry, it was resuspended in 50 μL of TE buffer. The concentration of DNA was 
measured using a Nanodrop Technologies spectrophotometer, which was blanked 
using TE buffer.  
 
2.3.3 Sequencing and aligning sequences on Geneious  
All 10 mini-prep isolated plasmid DNA samples were prepared and sent for 
sequencing. In a 5 μL reaction, 200 ng of plasmid DNA and 3.3 pmol of the WPRE N-
terminus reverse primer (2.3.1); with the remaining volume made up by sterile dH2O. 
Samples were sent to the University of Otago, Genetic Analysis Services (GAS) for 
sequencing. The returned sequences were analysed for sequence alignment with the 
expected sequence by Geneious.  
 
2.3.4 Midi-prep isolation of plasmid DNA (and re-sequencing for verification)  
Sequence verified plasmid-containing E.coli were grown in a flask of 300 mL of LB 
containing 100 μg/mL of ampicillin and inoculated with a scraping of glycerol stock. 
The flask was incubated in a 37 °C shaker overnight. The midi-prep was carried out 
according to instructions in the NucleoBond® Xtra Midi Plus high-copy plasmid DNA 
purification kit.  
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The bacterial cells were harvested in centrifuge tubes by centrifugation of the broth of 
overnight growth at 6000 x g for 10 minutes at 4 °C in a Beckman Avanti™ J-25 
centrifuge. The supernatant was discarded and the pellet resuspended by vortexing in 
8 mL of Resuspension buffer RES + RNaseA. For cell lysis, 8 mL of Lysis buffer LYS 
was added and mixed by gently inverting the tube and incubating at room temperature 
for no more than 5 minutes. While incubating, a NucleoBond® Xtra Column and filter 
are equilibrated by applying Equilibration buffer EQU to the rim of the filter and allowing 
to empty. 8 mL of Neutralisation buffer NEU is added to the lysate and mixed by gently 
inverting the tube. Immediately before loading the lysate onto the equilibrated column, 
the suspension is homogenised by gentle inversion again. Once the column has 
emptied, it is washed by applying Equilibration buffer EQU to the rim of the filter and 
allowing to empty. The filter is discarded. The NucleoBond® Xtra Column is washed 
with Wash buffer WASH. The plasmid DNA is then eluted using 5 mL of Elution buffer 
ELU and collected in a fresh centrifuge tube and 3.5 mL of  room temperature 
isopropanol was added and thoroughly vortexed for DNA precipitation. The 
precipitated plasmid DNA was centrifuged at 15000 x g for 30 minutes at 20 °C to 
pellet the DNA. The supernatant was discarded and the DNA pellet was washed with 
2 mL of 70% ethanol and centrifuged at 15000 x g for 5 minutes. The ethanol was 
discarded and the DNA pellet air dried.  
Once dry, it was resuspended in 150 μL of TE buffer. The concentration of DNA was 
measured using a Nanodrop Technologies spectrophotometer, which was blanked 
using TE buffer.  
The midi-prep isolated plasmid DNA was prepared in the same way as stated in (2.3.3) 
and sent to the University of Otago, Genetic Analysis Services (GAS) for sequencing. 
The returned sequence was verified for sequence alignment with the expected 
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sequence by Geneious.  
 
2.3.5 Glycerol stocks  
Glycerol stocks of transformed E.coli were made. Using aseptic techniques, 900 μL of 
overnight bacterial growth from mini-preps was added to 300 μL of sterile (autoclaved) 
UltraPure glycerol (Invitrogen) in 1.8 mL Nunc Cryotube Vials (Thermo Scientific) and 
vortexed well. Glycerol stocks were kept at -80 °C for long term storage.  
 
2.3.6 Viral constructs and packaging  
Midi-prep isolated plasmid DNA was packaged into lentivirus by Hollie Wicky of the 
NDD lab using methods described in Linterman et al., 2011. Viral construct tested in 
vitro on primary neurons. 0.5 μL and 2 μL of the generated LV construct was 
administered to 2 wells of primary neurons. They were allowed to incubate overnight 
before fixing.  
Immunochemistry was carried out with anti-GFP to enhance the fluorescence signal; 
protocol described in section (2.9).  
 
2.4 Virus used 
Use of lentivirus for in vivo mouse brain experiments was approved by the 
Environmental Risk Management Authority (ERMA), now the Environmental 
Protection Agency (EPA) under approval number GMD002851.  
The LV-pRRLSIN-PGK-GFP vector was pseudotyped with Rb B19 envelope 
glycoprotein with the GFP reporter gene expressed under the constitutive yeast 
phosphoglycerate kinase (PGK) promoter (Hawleym et al. 1994; Qin et al., 2010). It 
has a functional titre of 2.2 x 108 TU/mL. The LV-pCDH-pSyn-SP-GFP-sAPPα-T2A-
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mCherry vector has a functional titre of 2 x 109 ssRNA/mL.  
AAV use for in vivo mouse experiments was similarly approved by the EPA but under 
approval number GMD101582. The AAV9 vector was purchased and imported (under 
approval GMC100166) from the University of Pennsylvania. It has a genomic titre of 
3.6 x 10e13 genomes/mL  
 
2.5 Animals and treatment groups  
All animal procedures were reviewed and approved by the Animal Ethics Committee 
(AEC) of the University of Otago under AEC approval number: 106/11. Animal 
handling and Restricted Veterinary Medicine (RVM) drug usage and administration 
was taught and certified by the Animal Welfare Office (AWO) with a refresher course 
conducted (online) every 12 months.  
A total of 41 male mice were used, all were between 3 to 4 months old at the time of 
vector injection and each weighing between 25-37 g. The animals used were wildtype 
mice (strain C57BL/6) sourced from the Hercus Taieri Resource Unit (HTRU). Mice 
from each surgery group were housed together until the day of surgery; when they 
were separated into individual cages. They were housed singly post-surgery (due to 
mutual removal of sutures observed in the first surgical group) and were monitored for 
5 days post-surgery to ensure that none were experiencing adverse side effects from 
the surgery (eg. pain, dehydration, weight loss). Mice were fed and watered ad libitum 





Treatment  Animal no.  
No virus control  1  
5% w/v dextran (O/N)  4  
LV (7 days) 1  
LV (14 days)  3  
LV (28 days)  12  
AAV9 (28 days)  4  
AAV9 – 1:10 dilution (28 days)  4  
LV + mannitol (28 days)  4  
AAV9 (1:10 dilution) + mannitol (28days)  4  
Table 2.5 – Summary of treatment groups and animal numbers  
 
2.6 Stereotaxic surgery  
Animals were anaesthetised in preparation for surgery via a subcutaneous (SC) 
injection (into the loose skin at the hind legs) with an anaesthetic cocktail consisting of 
ketamine, domitor (both anaesthetics) and atropine (prevents lung congestion) (KDA) 
(refer to Appendix for drug concentrations, dosages and suppliers). Once 
anaesthetised, the mouse was tested for pain sensation with paw pinches, until no 
limb withdrawal reflex is observed, before proceeding. The dorsal region of the mouse 
head was shaved using an electronic clipper to expose the scalp. Another SC injection 
of lopaine (pre-op analgesic) was delivered into the dorsal region of the head, at the 
site of incision.  
The stereotaxic frame and work areas are wiped down with 70% ethanol, stereotaxic 
surgery tools (scalpel, surgical scissors, tweezers and needle holder) are autoclaved 
prior to use, immersed in hibitane when not in use and dried on a clean paper towel 
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before use. The mouse was secured in a stereotaxic frame with blunt 45° ear bars 
(chosen to prevent tympanic rupture) and tooth bars (World Precision Instruments 
(WPI); item#: TAXIC-650). The exposed scalp was cleaned with a swab dipped in 
hibitane before an incision was made sagittally using a sterile scalpel to reveal the 
skull. The reference point of Bregma (commonly used as a ‘zero-point’ landmark for 
stereotaxic surgery of the brain) where the coronal and sagittal sutures intersect 
perpendicularly was located and recorded; the coordinates for the injection were 
located at -2.2 mm anteroposterior (A-P) and +1.4 mm mediolateral (M-L) relative to 
Bregma (coordinates: A-P -2.2 mm/M-L +1.4 mm). A burr hole was carefully drilled in 
the skull at the appropriate stereotaxic coordinates.  
The dorsoventral (D-V) coordinate of the brain surface was recoded as the depth at 
which the needle bevel was observed to make contact with the cortex. The injection 
D-V coordinate is calculated relative to this ‘zero-point’.  
The infusate (5% w/v dextran, LV or AAV9) was administered using a NanoFil 10 μL 
syringe (WPI; #NANOFIL) coupled with a 33 gauge (33G) beveled NanoFil needle 
(WPI; #NF33BV-2). The needle and syringe is affixed into the UltraMicroPump (WPI; 
#UMP3), which depresses the needle, attached to the stereotaxic frame. A Micro4™ 
MicroSyringe Pump Controller (WPI; #SYS-MICRO4) is connected to the 
microinfusion pump to control the infusion rate.  
A unilateral injection is made by lowering the 33G needle slowly to the required depth 
into the dorsal hippocampus to a depth of 1.3 mm (coordinate: DV -1.3mm) (to target 
the CA1 hippocampus). The microinfusion pump controlled the delivery of the infusate 
was dispensed, the needle was left in place for a minimum of 5 minutes before being 
slowly withdrawn from the brain over 3 minutes.  
The open head wound was then cleaned, closed and sutured. Norocarp (an anti-
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inflammatory) and antisedan (for anaesthetic reversal) was then administered 
subcutaneously, along with 250 µL of 0.9% saline.  
 
2.6.1 5% w/v dextran administration  
The 5% w/v dextran solution was prepared on the day of surgery using fluorescently 
labelled Tetramethylrhodamine dextran of molecular weight 10 kDa (Molecular 
Probes) in sterile dH2O. These surgeries served as practice surgeries to gain 
clearance from the AWO for solo surgeries and to determine accuracy of the injection 
coordinates at targeting the CA1 region of the hippocampus.  
The dextran injections were carried out under PC1 conditions, in the small animal 
surgery room of the Hercus Animal Facility. Mice were prepared as previously 
described and injected with 200 μL of dextran. Perfusion and tissue collection took 
place the following day.  
 
2.6.3 Mannitol pre-treatment  
The mannitol solution was prepared on the day of the surgery by dissolving D-mannitol 
(Sigma-Aldrich; M4125-100G) in sterile water.  
Once anaesthetised, the mice in the treatment group received an intraperitoneal (IP) 
injection of a 25% w/v mannitol solution at a single dose of 3 mL/100g of bodyweight 
(Carty et al., 2010) approximately 15-20 minutes prior to vector injection. Each mouse 
was observed for any signs of pain (such as twitching, arched back, writhing, 
staggering, flinching or pressing of the belly) resulting from mannitol administration. 
No signs of pain was observed.  
Previous studies have used a control group which were given an IP injection of saline 
(along with the subsequent intracranial viral injection). However, due to the consensus 
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in the literature (which did not show any significant difference in transduction levels 
due to saline injection) and time constraints; the control used to compare transduction 
efficiencies of either LV or AAV vectors with mannitol treatment will be the mice 
injected with the respective vector alone.  
 
2.6.4 Viral vector administration  
All viral aliquots were collected the morning of surgeries and transported on dry ice 
from the Department of Biochemistry to the Hercus Animal Facility in accordance with 
containment controls outlined by HTRU Standard Operating Procedures; in an 
additional sealed and biohazard labelled container.  
All viral injections were carried under PC2 conditions in the biobubble of the large 
animal surgery room (H408) of the Hercus Animal Facility. Mice were prepared as 
previously described and 1 µL of either LV or AAV9 vector was injected into the left 
dorsal hippocampus at a rate of 150 nL/min.  
LV and AAV9 injections were always scheduled for different days. Different needles 
used for either LV or AAV9; and where possible, a different syringe was used for the 
different viral vectors. Otherwise, the syringe was cleaned out by flushing out with 
viraclean followed by a triple wash of sterile dH2O prior to using a different viral vector.  
 
2.7 Tissue collection 
Mice were killed after the set incubation period. Euthanasia was achieved with an 
overdose of sodium pentobarbital. Immediately following euthanasia, the mouse had 
its chest cavity opened and a butterfly needle was inserted into the heart at the apex. 
A small snip was made using surgical scissors at the right atrium and the mouse was 
first perfused with 20 mL of 0.9% saline, followed by 20 mL of freshly prepared 4% 
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paraformaldehyde in 0.1 M PB (PFA).  
The head was removed and the brain was carefully dissected out of the skull and 
immersed in approximately 10 mL of fresh 4% PFA in a foil wrapped (to prevent photo-
bleaching) sterile universal for 24 hours. This is followed by floating the brain in 30% 
sucrose solution for cryoprotection until the brain has sunk (usually 36-48 hours later).  
Each brain was individually fixed in a Peel-A-Way® embedding molds (Polysciences, 
Inc.; 18646A-1) by freezing in Tissue-Tek® O.C.T™ (optimal cutting temperature) 
Compound (Sakura; 4583) using dry ice and isopropanol. The cryofixed brains were 
stored at -80 °C until sectioning.  
Serial coronal sections were taken at 50 µm thickness using a Research Cryostat 
Leica CM3050 (-20 ˚C). Each section was stored in a well of 100 μL of cryoprotectant 
solution (Solutions appendix) in a 96-well plate. One brain typically required two 96-
well plates. Plates were wrapped in foil and kept at -20 °C until required for imaging.  
 
2.8 Imaging  
Every sixth section was transferred into a well of 0.1 M PB in a 24-well plate to wash 
off any O.C.T and/or cryoprotectant solution overnight. Sections were mounted on 
slides with antifade to preserve fluorescence and viewed under an Olympus inverted 
fluorescence research microscope IX71 to locate GFP reporter gene expression in 
transduced cells.  
Sequential images were captured of whole sections which were then merged together 
using Adobe® Photoshop® CS6 (Version 13.0 x64) to generate a composite image of 
the section. Using the composite image, regions of GFP expression were mapped 





2.9.1 Immunohistochemistry for cell type analysis  
The indirect method of immunohistochemistry (IHC) was carried out on tissue sections 
for neuronal marker, NeuN, using a mouse monoclonal anti-NeuN (Millipore; MAB 
377); astrocyte marker, GFAP, using a mouse monoclonal anti-GFAP (Sigma Aldrich; 
G3893); and in certain cases, for GFP, using a rabbit polyclonal anti-GFP (Abcam; 
Ab290). The labelled secondary antibody for anti-NeuN and anti-GFAP was Alexa 
Fluor 594 Goat anti-mouse IgG (Invitrogen NZ; A-11037). The secondary antibody for 
anti-GFP was Alexa Fluor 488 Goat anti-rabbit (Invitrogen NZ; A-11008). The table 
below summarises the anitbodies and the dilutions used.  
Antibody  Dilution  
Primary antibodies  Anti-GFAP 1:1000 (IHC)  
Anti-GFP 1:1000 (IHC and ICC)  
Anti-NeuN 1:1000 (IHC)  
Secondary antibodies  Alexa-Fluor 488  1:1000 (IHC and ICC)  
Alexa-Fluor 594  1:1000 (IHC)  
Table 2.6 – antibodies and dilutions used in immunohistochemistry and immunocytochemistry  
 
Sections were prepared for IHC by 3 washes of 30 minutes each in 1 mL of PBS in 
24-well plates at room temperature (or an overnight wash in PBS at 4 °C if taken 
directly from cryoprotectant. Blocking, to prevent non-specific antibody binding, was 
carried out by incubating sections in blocking solution for 1 hour at room temperature.  
The rabbit polyclonal anti-GFP was highly non-specific, which meant it required an 
additional pre-block step to remove non-specific binding antibodies. This involved 
adding the required volume of primary antibody to 1 mL of blocking solution and adding 
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500 μL to two wells containing GFP absent tissue for non-GFP-specific antibodies to 
bind. This pre-block was incubated for 1 hour at room temperature (while tissue 
blocking is taking place). The 1 mL of primary antibody was removed from the wells 
(now free of non-GFP-specific binding antibodies) and topped up with blocking solution 
to the working dilution.  
The primary antibody mixture was prepared to the desired dilution and the blocking 
solution was removed from the well before adding the primary antibody at 1 mL per 
well. The plate was parafilmed, foil wrapped and incubated at 4 °C for 2 days.  
The primary antibody was removed and 3 washes of 30 minutes each with 1 mL of 
PBS-T to remove unbound and weakly bound primary antibody. The secondary 
antibody was prepared to the required dilution and 1 mL was added per well after 
removal of the third PBS-T wash. The plate was again parafilmed, foil wrapped and 
incubated for 4 hours at room temperature on a shaker.  
The secondary antibody was removed and three 30 minutes washes with PBS-T was 
repeated to remove unbound and weakly bound secondary antibody. PBS was added 
after removal of the final wash.  
A 1:10,000 dilution solution of DAPI (Sigma NZ; D9564) Nuclear Stain was prepared 
and 1 mL was added per well after removal of PBS. Incubation was 15 minutes at 
room temperature.  
 
2.9.2 Immunocytochemistry of transduced cell for viral testing  
Immunocytochemistry (ICC) of primary neurons transduced with LV-pCDH-pSyn-SP-
GFP-sAPPα-T2A-mCherry used anti-GFP primary antibody and its respective 
secondary.  
The ICC protocol with the rabbit polyclonal anti-GFP is identical to the IHC protocol as 
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listed above (2.9.1). It only differed in antibody incubation times; the primary antibody 
was incubated overnight at 4 °C while secondary antibody incubation was 90 minutes 
at room temperature. Cells were not DAPI stained before imaging.  
 
2.10 Image analysis  
2.10.1 Quantifying area of fluorescence  
The composite images were then analysed using the program ImageJ (1.48v) to 
determine the area of fluorescence within each section.  
The original image is first converted into a binary image and the fluorescence appears 
black while all other colour is converted to white background. The analysis is then 
scaled according to known distances in the original image by using the scale bar. The 
program then calculates the black area to produce the area transduced within that 
section (Appendix). The area obtained is recorded relative to its mapped position in 
the mouse atlas.  
 
2.10.2 Cell counting for determining viral titre  
An experiment was designed to examine for a possible direct effect of mannitol 
presence (at different concentrations) on lentiviral titre. HT1080 cells were prepared 
in a 24-well plate by Hollie Wicky. The LV used in this experiment was the rabies B19 
pseudotyped GFP expressing virus (LV-pRRLSIN-PGK-GFP) and 0.5 μL was added 
into the media of each well.  
Five concentrations were prepared; 5, 12.5, 15, 20 and 25% w/v mannitol, along with 
an untreated (LV only) control. Mannitol was administered at a relative concentration 
to be used for in vivo experiments of 3 mL/100mL of media. This translated to 3 μL of 
each concentration added to 1 mL of media per well.  
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Two methods of administration was used; a sequential and co-administration of 
mannitol with LV. The sequential method involved adding mannitol into the well before 
introducing the virus. Co-administration involved adding the 0.5 μL of LV into 30 μL of 
mannitol before adding the total volume into the media of each well.  
Transduction was allowed to occur overnight before fixing the cells for 
immunocytochemistry with GFP antibody (2.9.1). Primary antibody incubation was 
carried out overnight at 4 °C. Secondary antibody incubation was carried on the shaker 
for 90 minutes at room temperature.  
A functional titre was calculated by taking 5 frames of each well under a fluorescence 
microscope. The cell count in each frame was determined using ImageJ to carry out 
an automated cell count (Appendix C).  
 
2.11 Statistical analysis  
Statistical analysis of anterior-posterior distance of GFP expression spread was 
conducted in Microsoft Office Excel to carry out t-tests to generate p-values.  
To generate plots illustrating a scaled mean for each treatment group, code written by 
Dr Michael Black, of the Department of Biochemistry, was used. The raw data was 
entered into RStudio (Version 0.99.442) to generate a plot. That unscaled data was 
scaled against its mean to zero to generate a scaled plot. Using that scaled plot, a 






Chapter 3: Results  
Following the incubation period post-injection, all mice were perfused, with brains fixed 
and cryoprotected for analysis. All the following mouse brain images shown are of 50 
μm coronal sections. Sections are oriented to display in a posterior to anterior direction 
of view (ie. The orientation is true to view; left and right hemispheres are on the left 
and right of the image shown). All microscopy images were taken on an Olympus 
inverted fluorescence research microscope IX71. Images of whole sections were 
taken and mapped to determine distance of spread and specific regions of GFP 
expression. Area of fluorescence was calculated to determine distribution across that 
distance.  
 
3.1 Using 5% w/v Dextran to verify injection coordinates  
These initial Dextran injections were conducted at the same stereotaxic coordinates 
(2.6) at a depth 1.00 mm ventral of the brain surface. Two hundred nanolitres of 
Dextran dye (molecular weight: 10,000 Da) was injected into the left dorsal 
hippocampus. Figure 3.1 shows the staining observed within the left hippocampus 






Figure 3.1 – 5% w/v Dextran stained mouse hippocampus  
Labelled regions of Dextran staining – Or: oriens layer; LMol: lacunosum moleculare layer; Mol: 
molecular layer of the dentate gyrus (section at approximately 1.94 mm posterior to bregma). Animal 
ID: IC007; scale bar 500 μm.  
 
The shallower injection results in strong staining in the oriens layer of the hippocampus 
dorsal to the CA1 and CA2 regions of the hippocampus, the molecular layer of the 
dentate gyrus (DG) and into the lacunosum moleculare layer of the hippocampus 
formation.  
Due to the depth of injection mostly delivering the Dextran to the oriens layer of the 
hippocampus, it was decided to change the depth of injection to -1.3 mm dorsal-ventral 
(D-V). Proceeding forward, all viral vector injections were conducted at the new depth 
to improve targeting of the CA1 region of the hippocampus proper.  
 
3.2 Determining ideal timeframe for viral vector incubation  
An initial trial was conducted to determine the incubation times for future treatment 
groups; 7, 14 and 28 days were trialled. 7 and 14 days were insufficient time to produce 
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expression beyond the immediate injection time (results not shown). In the end, 28 
days was chosen to allow ample time for transgene expression and as it provided 
enough time for analysis between surgery groups.  
 
3.3 Spread of lentivirus-mediated expression of GFP  
One microliter of the rabies pseudotyped GFP expressing LV (titre: 2.2 x 108 
(transducing units) TU/mL) was injected into the left dorsal hippocampus at a depth of 
1.30 mm. Perfusion and analysis took place 28 days post-injection.  
 
 
As observed in Figure 3.2, LV-mediated GFP expression was largely limited to the 
hippocampal regions of the injection site.  
Regions of the hippocampus with observed GFP expression at and posterior to the 
injection site included the CA1, pyramidal cell layer, granular and polymorph layer of 
Figure 3.2 – LV injected mouse brain sections 
showing GFP expression  
Most posterior to most anterior sections with 
GFP expression showing extent of LV spread.  
A: most posterior section (bregma -2.54 mm)  
B: approx. injection site (bregma -2.18 mm)  
C: most anterior section (bregma -1.06 mm)  
Animal ID: IC028; scale bar 500 μm.  
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the dentate gyrus, lacunosum moleculare layer and dorsal hippocampal commissure. 
(Figure 3.2A and 3.2B; magnified in Figure 3.3).  
 
Figure 3.3 – Magnified mouse hippocampus at site of LV injection  
Labelled regions of GFP expression – dhc: dorsal hippocampal commissure; Py: pyramidal cell layer; 
LMol: lacunosum moleculare layer; PoDG: polyporph layer of the dentate gyrus (DG); GrDG: granular 
layer of the DG. Animal ID: IC028; scale bar 500μm.  
 
There were fewer cells transduced anteriorly and those observed were found to be in 




Figure 3.4 – Magnified anterior hippocampus of LV injected mouse  
Labelled regions of GFP expression – Or: oriens layer; Py: pyramidal cell layer; SLu: stratum lucidum. 
Animal ID: IC028; scale bar 500μm.  
 
The stratum lucidum is mainly composed of densely packed mossy fibres and 
interneurons projecting to CA3 pyramidal cells or the stratum oriens below. The CA1, 
hilur regions and lacunosum moleculare layer of the hippocampus also receive axonal 
projections from the interneurons of the stratum lucidum (Vida & Frotscher, 2000). 
These projections and connections within the hippocampus explain the spread of GFP 
expression to distal region from the injection site.  
 
3.3.1 Distribution of spread from bregma achieved with LV injections  
The area of fluorescence was determined using ImageJ (Appendix C) and saved into 
a spreadsheet. Using code written by Dr Michael Black of the Departmetn of 
Bichemistry, the raw data was entered into RStudio (Version 0.99.442) to generate a 
plot. That unscaled data was scaled against its mean to zero to generate a scaled plot. 
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Using that scaled plot, a mean trendline of the treatment group was generated as 
shown below.  
 
Figure 3.5 – Graph of scaled area of fluorescence and mean trendline of LV treated group  
Mean (in black line) and 95% confidence interval (CI; grey band) 
 
Because the plot was generated with an x-axis representing Bregma, a single off-
target injection site (animal ID: IC006) skewed the data set and the resulting mean 
trendline. However, the tight grouping and narrow spread is indicated on the plot 
indicating a very narrow distribution of GFP expression and thus LV spread. The left 
peak on the mean trendline where most of the on-target injections are centred is at 
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approximately -2.25 mm relative to bregma indicating that on average the injections 
and spread were close to the injection coordinate of -2.2 mm relative to bregma.  
 
3.4 Spread of undiluted AAV9-mediated expression of GFP  
One microlitre of AAV9 (titre: 3.6 x 10e13 genomes/mL) was injected unilaterally into 
the left CA1 region of the hippocampus at a depth of 1.30 mm. Perfusion and analysis 
took place 28 days post-injection.  
 
 
As observed in Figure 3.6, the undiluted AAV9 injection resulted in widespread and 
robust transduction (while not shown, GFP was observable with the naked eye in the 
cortex during dissection of the brain).  
Posterior to the injection, GFP expression extended to large regions of the cerebellum. 
These included the 4th and 5th cerebellar lobules, simple lobule (not shown in magnified 
Figure 3.6 – Undiluted AAV9 injected mouse brain 
sections showing GFP expression  
A: most posterior section (bregma -6.24 mm)  
B: approx. injection site; label Ctx: cortex  
(bregma -2.46 mm)  
C: most anterior section (bregma 2.58 mm)  





image), inferior cerebellar peduncle, crus 2 and 1 of the ansiform lobule and 
paraflocculus (Figure 3.6A; magnified in Figure 3.7).  
 
Figure 3.7 – Magnified cerebellum of undiluted AAV9 injected mouse  
Labelled regions of GFP expression – 4&5Cb: 4th and 5th cerebellar lobules; icp: inferior cerebellar 
peduncle; Crus1/2: crus 1/2 (respectively) of the ansiform lobule; pfs: paraflocculus. Animal ID: IC017; 
scale bar 500 μm.  
 
In the medulla, there is strong expression of the pyramidal tract (which travel to the 
brain stem or spinal cord) and raphe pallidus nucleus. Motor neuron fibres in the 
pyramidal tract originate from pyramidal cells in layer V of the cortex, which show high 
levels of transduction (Figure 3.6B; label “Ctx”). Projections from the reticular nuclei 
(which is visible as GFP fluorescent fibres in Figure 3.6A; magnified in Figure 3.8) 




Figure 3.8 – Magnified medulla of undiluted AAV9 injected mouse  
Labelled regions of GFP expression – PCRtA: parvocellular reticular nucleus (α part); IRt: intermediate 
reticular nucleus; Gi: gigantocellular reticular nucleus; py: pyramidal tract; RPa: raphe pallidus nucleus. 
Animal ID: IC017; scale bar 500 μm.  
 
The reticular formation resembles a ‘highway’ of neuronal projections from various 
parts of the brain. It is likely due to this diverse network of projections which resulted 
in the high level of transductions seen. It is split into 3 columns; of which the raphe 
pallidus nucleus forms the median column. The lateral column is known as the 
parvocellular reticulus nucleus and is highly transduced (regions with GFP expression 
are the gigantocellular (Gi), Gi α-part, lateral paragigantocellualr and intermediate 
reticular nuclei).  
Around the injection site, there is almost complete transduction of all nearby structures 
(Figure 3.6B). This is a marked difference, even within the immediate site of injection, 
in the level of transduction and GFP expression in the contralateral hemisphere; 
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compared to the LV vector where most contralateral GFP expression came from the 
corpus callosum and the occasional cell in the subiculum.  
The left injected hippocampus is almost completely transduced especially within the 
CA1 to CA3 region; with fewer cells transduced in the dentate gyrus (magnified in 
Figure 3.9). All regions of the cortex were transduced; although the secondary auditory 
cortex had lower GFP expression levels. The cortical regions immediately dorsal to 
the hippocampus, such as the retrosplenial and visual cortex, exhibit high levels of 
transduction. It is not known if this might be caused (to some extent) by a combination 
of backflow of virus during needle removal and/or greater transduction efficiency of 
AAV9. There was also very clear GFP expression in the entorhinal cortex due to 
retrograde transport along projections between the two structures. Superficial layer III 
of the entorhinal cortex projects to the CA1 region of the hippocampus and subiculum; 





Figure 3.9 – Magnified mouse hippocampus at site of undiluted AAV9 injection  
Labelled regions of GFP expression – RSG: retrosplenial granular cortex; RSA retrosplenial agranular 
cortex; Vc: visual cortex; Or: oriens layer; Py: pyramidal cell layer; LMol: lacunosum moleculare layer; 
Mol: molecular layer of the dentate gyrus; DG: dentate gyrus. Animal ID: IC017; scale bar 500μm.  
 
Anterior to the injection site, GFP expression was observed throughout the frontal 
association, prelimbic and orbital cortex of both the left and right hemisphere (Figure 
3.6C; labelled in Figure 3.10). GFP expression is restricted to the dorsal and ventral 
tenia tecta, olfactory nucleus, and plexiform layer and cell layer of the olfactory bulb of 
the left hemisphere. However, the intrabulbar part of the anterior commissure 




Figure 3.10 – Most anterior GFP expressing section of undiluted AAV injected mouse  
Labelled regions of GFP expression – AOD/L/M/V: anterior olfactory nucleus, dorsal/lateral/ 
medial/ventral part; PrL: prelimbic cortex; FrA: frontal association cortex; M/V/L/DLO: 
medial/ventral/lateral/dorsolateral orbital cortex; aci: anterior commissure, intrabulbar part; VTT ventral 
tenia tecta. Animal ID: IC017; scale bar 500 μm.  
 
From a visual inspection, the AAV9 vector demonstrated a greater ability to spread 
from the injection site to far distal regions of the brain compared to a rabies-




3.4.1 Distribution of spread from Bregma achieved with undiluted AAV9 injections 
 
Figure 3.11 – Graph of scaled area of fluorescence and mean trendline of undiluted AAV9 
treated group  
Mean (in black line) and 95% confidence interval (CI; grey band) 
 
The plot produced from the area of fluorescence of undiluted AAV treated brains has 
a much wider spread as expected from the fluorescence microscopy images. The peak 
of the mean trendline (indicating largest area of fluorescence, and hence the injection 
site) is centred approximately -2.25 mm relative to bregma which is where it is 




3.5 Spread of (1:10) diluted AAV 9-mediated expression of GFP  
The dilution was prepared at the start of the day of surgery; a 5 μL aliquot of virus was 
thawed on ice, under PC2 conditions. Fifty microlitres of dPBS was added and pipetted 
gently to mix; before transporting on dry ice to the animal facility.  
One microlitre of the diluted AAV9 (titre: 3.6 x 10e12 genomes/mL) was injected 
unilaterally into the left CA1 region of the hippocampus at a depth of 1.30 mm. 
Perfusion and analysis took place 28 days post-injection.  
 
 
As observed in Figure 3.12, there was widespread expression of GFP in distal regions 
from the hippocampus in brains transduced with the 1:10 diluted AAV9 aliquot. 
Visually, there were fewer cells transduced from the deceased intensity of GFP 
fluorescence. However similar regions were transduced when compared to the 
undiluted AAV9 injected brains.  
Figure 3.12 – (1:10) diluted AAV injected mouse 
brain section showing GFP expression  
A: most posterior section (bregma -5.8 mm)  
B: approx. injection site (bregma -2.06 mm)  
C: most anterior section (bregma 2.58 mm) 
Animal ID: IC031; scale bar 500 μm.  
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Posterior to the injection site, GFP expression was limited to the pyramidal tract 
(Figure 3.12A; magnified in Figure 3.13) and did not exhibit the same transduction of 
the reticular formation as was seen in the medulla of the undiluted AAV9 injected brain 
(Figure 3.8). No GFP expression was observed in the cerebellum.  
 
Figure 3.13 – Magnified medulla of diluted AAV9 injected mouse  
Labelled regions of GFP expression – py: pyramidal tract. Animal ID: IC031; scale bar 500μm.  
 
Similarities in transduction patterns to the undiluted AAV9 brains include widespread 
GFP expression within the left hippocampus with expression levels consistent through 
most regions of the hippocampus formation (Figure 3.12B). The CA1 to CA3 regions 
of the left hippocampus proper exhibit high levels of transduction along with the various 
layers cell layers of the dentate gyrus. The contralateral hippocampus formation is not 
as evenly transduced; the hippocampus proper is GFP expressing from CA1 to CA3 




Figure 3.14 – Magnified hippocampus of diluted AAV9 injected mouse  
Labelled regions of GFP expression – LMol: lacunosum moleculare layer; Mol: molecular layer of the 
dentate gyrus; DG: dentate gyrus. Animal ID: IC031; scale bar 500 μm.  
 
Cortical transduction was also limited to the retrosplenial, parietal association, primary 
and secondary somatosensory, secondary auditory and temporal auditory cortices. 
There is also some GFP expression in the entorhinal cortex. Contralateral cortical 
transduction is largely absent in comparison to the undiluted AAV9 injected mouse 
brains; although some spread along the corpus callosum is visible.  
Ventral to the hippocampus, transduction is also limited to the ipsilateral hemisphere. 
Regions with observed GFP expression include the dorsal laeral geniculate nucleus, 
lateral posterior thalamic nucleus and reticular thalamic nucleus. Spread towards more 
ventral regions was observed along the stria terminalis, internal capsule and zona 
incerta. The fornix and perifornical nucleus is transduced. The contralateral fornix is 
also transduced.  
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In the anterior regions, expression is visibly reduced compared to the brains injected 
with undiluted AAV9. The regions are weakly transduced and limited to the prelimbic 
cortex and medial to ventral orbital cortex (Figure 3.15).  
 
Figure 3.15 – Most anterior GFP section of diluted AAV9 injected mouse  
Labelled regions of GFP expression – PrL: prelimbic cortex; VO: ventral orbital cortex. Animal ID: IC031; 




3.5.1 Distribution of spread from bregma achieved with 1:10 diluted AAV9 injections  
 
Figure 3.16 – Graph of scaled area of fluorescence and mean trendline of diluted AAV9 treated 
group  
Mean (in black line) and 95% confidence interval (CI; grey band) 
 
The mean trendline for the diluted AAV9 has a narrower distribution compared to the 
undiluted AAV9 treatment group. This indicates a relatively lower volume of GFP 
expression which is an expected outcome from a diluted/lower titre of virus. However, 
the spread anterior to posterior is not significantly different and the peak of the mean 




3.6 Effects of mannitol pre-treatment  
3.6.1 Effects on lentiviral-mediated expression of GFP  
The 25% w/v mannitol solution was administered systemically via an intraperitoneal 
injection after anaesthetising and before beginning surgery and viral vector injection. 
One microlitre of the same rabies B19 pseudotyped GFP expressing LV (titre: 2.2 x 
108 TU/mL) was injected into the left dorsal hippocampus at a depth of 1.30mm. 
Perfusion and analysis took place 28 days post-injection.  
 
Figure 3.17 – Systemic mannitol pre-treatment with LV injected mouse brain sections  
No GFP expression was found; sections chosen from the most posterior and anterior sections available 
along with the approximate injection site to illustrate no observable GFP. A: most posterior section 
(bregma -6.36mm); B: approximate injection site (bregma -2.18mm); C: most anterior section (bregma 
2.10mm). Animal ID: IC021; scale 500μm.   
 
No GFP expression was observed in any of the 4 brains from the LV + mannitol 
treatment group. It is unknown why there would fail to be any observable sign of GFP 
expression. An unsuccessful attempt to stain for GFP was also made in an effort to 
enhance a weak GFP signal.  
The virus was identical to what was used in the first LV surgery and was known to be 
functional and all transport and handling procedures were identical in all other 
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injections. Virus was dispensed during the injection as the expected volume had been 
infused from the syringe after each animal.  
This negative result prompted an in vitro experiment using primary neurons to test for 
any adverse effect that mannitol might be having on viral titre and thus transduction 
efficiencies (viii).  
 
3.6.2 Effects of mannitol on (1:10) diluted adeno-associated virus serotype 9-mediated 
expression of GFP  
The 25% w/v mannitol solution was administered systemically via an intraperitoneal 
injection after anaesthetising and before beginning surgery and viral vector injection. 
One microlitre of 1:10 diluted AAV9 (titre: 3.6 x 10e12 genomes/mL) was injected into 
the left dorsal hippocampus at a depth of 1.30 mm. Perfusion and analysis took place 





With mannitol pre-treatment, AAV-mediated GFP expression distribution and pattern 
resembled those found in brains injected with undiluted AAV9; except for GFP 
expression in the hippocampi all four brain was lacking which does not seem likely to 
have happened due to a missed injection site across all four mice.  
Posterior to the injection site, the pyramidal tract and mossy fibres also strongly 
expressed GFP (Figure 3.18A; magnified in Figure 3.19), similar to what was observed 
in the undiluted AAV9 injected mouse brains. However, no GFP expression was 
observed in the cerebellum.  
Figure 3.18 – Systemic mannitol pre-treatment with 
diluted AAV9 injected mouse brain sections  
A: most posterior section (bregma -7.08mm)  
B: approximate injection site (bregma -2.06mm)  
C: most anterior section (bregma 2.34mm)  





Figure 3.19 – magnified medulla of diluted AAV9 injected mouse with mannitol pre-treatment  
Labelled regions of GFP expression – PCRt: parvocellular reticular nucleus; IRt: intermediate reticular 
nucleus; Gi: gigantocellular reticular nucleus; py: pyramidal tract. Animal ID: IC023; scale bar 500 μm.  
 
At the injection site, hippocampal transduction was markedly reduced compared to 
both diluted and undiluted AAV9 injected in all four mice. Some hippocampal neurons 
expressing GFP, towards the lateral region of CA1 and through CA2 and 3, are the 
extent of transduction; along with the subiculum (Figure 3.18B; magnified in Figure 





Figure 3.20 – Magnified mouse hippocampus at site of diluted AAV9 injection with mannitol pre-
treatment 
Labelled regions of GFP expression – RSG: retrosplenial granular cortex; RSA retrosplenial agranular 
cortex; M/LPtA: medial/lateral parietal association cortex; V2L: secondary visual cortex; Or: oriens layer; 
PoDG: polymorph layer of the dentate gyrus; S: subiculum. Animal ID: IC023; scale bar 500 μm.  
 
The extent and regions of GFP expression in the cortex was similar to brains injected 
with undiluted AAV9, but at lower levels with fewer cells transduced. Regions of GFP 
expression included the retrosplenial granular and agranular cortices, medial and 
lateral parietal association cortices, secondary visual and primary somatosensory 
cortices (Figure 3.20). The temporal association cortex, entorhinal and perirhinal 




Figure 3.21 – Lateral cortical region of section at the site of diluted AAV9 injection with mannitol 
pre-treatment  
Labelled regions of GFP expression – TeA: temporal association cortex; Ect: entorhinal cortex; PRh: 
perirhinal cortex. Animal ID: IC023; scale bar 500 μm.  
 
In the anterior regions, GFP expression was higher than that observed in diluted AAV9 
injected brains. Particularly in the dorsal left hemisphere, where expression closely 
resembled brains injected with undiluted AAV9; all regions express GFP strongly 
except for the medial regions; such as the cingulate cortex, area 1, prelimbic cortex 
and medial orbital cortex, which are weakly transduced. Ventrally, weak GFP 
expression is observed mostly in the anterior olfactory nucleus. The contralateral 




Figure 3.22 – most anterior GFP expressing section of diluted AAV injected mouse brain with 
mannitol pre-treatment  
Labelled regions of GFP expression – CG1: cingulate cortex, area 1; PrL: prelimbic cortex; M/V/LO: 
medial/ventral/lateral orbital cortex; AI: agranular insular cortex; M1/2: primary/secondary motor cortex; 




3.6.3 Distribution of spread from bregma achieved mannitol pre-treatment on (1:10) 
diluted adeno-associated virus serotype 9 injections  
 
Figure 3.23 – Graph of scaled area of fluorescence and mean trendline of diluted AAV9 with 
mannitol pre-treatment group  
Mean (in black line) and 95% confidence interval (CI; grey band) 
 
While the anterior to posterior distance of spread is still comparable to both undiluted 
and diluted AAV9 treatments, the curve is skewed towards the right; with the peak 
above bregma. This might either indicate a missed injection site or lower levels of 
expression around the injection coordinate or -2.2 mm relative to bregma due to the 
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lack of hippocampal expression; which is where a large proportion of GFP expression 
was observed in sections from diluted AAV9 injected brains.  
 
3.6.4 Comparing anterior-posterior distance of spread  
Firstly, the total anterior to posterior distance of spread was calculated from mapping 
the position of the most anterior and posterior sections where GFP expression was 
observed. The average distance within each treatment group was calculated and 
shown in the graph below (Figure 3.17); with the error bars indicating standard 
deviation within each treatment group. A 2-tailed t-test was applied in Excel to 
determine the p-value between treatment groups (Supplementary Figures). The null 
hypothesis was “the difference in spread between group 1 (array 1 of the t-test) vs. 
group 2 occurred by chance”. A p-value of less than 0.05 was deemed to be significant 
(ie. There was less than 0.05% chance of the null hypothesis being true; that difference 
in spread occurred by chance)  
 



























The LV mannitol group was left out as no GFP expression was observed. The LV 
injected brains averaged 1.98 mm of spread with the AAV9 undiluted, diluted and 
mannitol pre-treatment averaged 9.67, 8.52 and 9.375 mm respectively.  
The p-values calculated by comparing any one of the AAV9 treatment groups with 
another were all greater than 0.05; meaning AAV9 mediated GFP expression was not 
affected by viral titre or mannitol treatment.  
However, the p-values obtained when comparing LV mediated spread with all AAV9 
treatments were less than 0.05; indication that AAV9 produced a significantly greater 
anterior-posterior spread compared to LV.  
 
3.7 Immunohistochemistry of transduced cell type analysis  
3.7.1 Cell types transduced in lentivirus brains  
IHC staining of LV transduced brain with GFAP and NeuN was carried out as 





GFAP in an astrocyte marker and there is little co-localisation with GFP expressing 
cells and GFAP positive astrocytes (Figure 3.25B) indicates that the use of LV did not 
trigger an immune response.   
Figure 3.25 – LV injected mouse brain with 
anti-GFAP staining  
A: CA1/2 hippocampal neurons expressing GFP 
and GFAP staining.  
B: magnified hippocampal neuron; no co-
localisation of GFP neurons and GFAP positive 
cells.  
C: same hippocampal view as A; overlaid with 





Staining with NeuN allowed the visualisation of neuronal cells. The CA1 neurons of 
the LV transduced mouse brain are very distinctly expressing GFP. The GFP positive 
cell body are co-localised with NeuN staining (Figure 3.26) indicating that CA1 neurons 
were successfully transduced with LV injection into the hippocampus.  
 
Figure 3.26 – LV injected mouse brain with 
anti-NeuN staining 
A: CA1 hippocampal neurons expressing GFP 
and NeuN staining.  
B: magnified hippocampal neuron; co-
localisation of GFP neurons and NeuN positive 
cells.  
C: same magnified view as B; overlaid with 
DAPI nuclear stain.  
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3.7.2 Cell types transduced in AAV9 brains  
 
 
GFAP staining showed little to no co-localisation of transduced cells with astrocytes 
(Figure 3.27). This indicated that AAV had low immunogenicity within the brain, at least 
in this strain of mice. However, visually, it did seem that there was a higher level of 
GFAP staining in brain sections from AAV injected mice rather than LV treated mice. 
It would be difficult to say definitively without quantifying the levels of staining between 
the treatment groups.  
 
Figure 3.27 – AAV injected mouse brain with 
anti-GFAP staining  
A: CA2/3 hippocampal neurons strongly 
expressing GFP with GFAP staining.  
B: magnified CA2 hippocampal neurons; no co-
localisation of GFP positive neurons and GFAP 
stained astrocytes.  
C: same magnified view as B; overlaid with 





As seen in Figure 3.28A, NeuN staining was highly co-localised with AAV transduced 
hippocampal neurons, especially within the CA3 region. Individual cell bodies in the 
magnified image (Figure 3.28B) are shown to be co-localised with NeuN staining 
(appearing yellow when images are overlaid).  
 
Figure 3.28 – AAV injected mouse brain with 
anti-NeuN staining  
A: CA1 - CA3 hippocampal neurons expressing 
GFP with NeuN staining.  
B: magnified CA1 hippocampal neurons; no co-
localisation of GFP positive neurons and GFAP 
stained astrocytes.  
C: same magnified view as B; overlaid with 
DAPI nuclear stain.  
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3.7.3 Cell types transduced in AAV9 with mannitol pre-treated brains  
 
 
Most of the AAV and mannitol pre-treatment brains had little to no GFP expression 
within the hippocampus. In the section stained for NeuN, there was a lone CA1 neuron 
transduced (Figure 3.29B) which was difficult to determine co-localisation with the 
NeuN staining surrounding it. However some neurons do not produce NeuN but based 
on the location and morphology, it strongly suggests that it is a neuron.  
Images of GFAP staining on AAV and mannitol pre-treatment sections are 
unfortunately missing.  
 
Figure 3.29 – AAV injected with mannitol pre-
treatment mouse brain with anti-NeuN 
staining  
A: poor hippocampal expression of GFP with 
NeuN staining.  
B: magnified lone CA1 hippocampal neurons; 
co-localisation of GFP and NeuN staining 
difficult to determine.  
C: same magnified view as B; overlaid with 
DAPI nuclear stain.  
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3.7.4 GFP staining in LV with mannitol brains  
IHC staining with anti-GFP was attempted to enhance any possible weakly fluorescent 
signal in LV injected with mannitol pre-treatment brain section.  
 
 
Even with anti-GFP staining to enhance the signal, the fluorescent cells observed in 
Figure 3.30 was the extent of any fluorescence indicative of likely LV transduction 
which had occurred in the LV and mannitol pre-treatment group.  
 
Figure 3.30 – anti-GFP stained fluorescent 
cells in LV injected mouse brain with mannitol 
pre-treatment  
A: Fluorescent cell in the cortex.  
B: Fluorescent cells in the left entorhinal 
cortex. Taken at the same magnification as A  




3.8 Effect of mannitol concentration on lentiviral transduction  
The experiment was designed to examine for a possible effect of mannitol on lentiviral 
titre, and thus subsequently the number of cells transduced, which might have resulted 
in the lack of GFP expression in vivo.  
HT1080 cells were either sequentially administered or co-administered mannitol with 
lentivirus. Five different concentration of mannitol (up to the 25% w/v used for the in 
vivo experiments) were tested, together with a virus only control.  
For each concentration of mannitol, five field-of-view images were captured at 20x 
magnification. An image from each concentration of mannitol co-administered with LV 
is shown in Figure 3.31 below.  
 
Figure 3.31 - LV transduced HT1080 cells at different concentrations of mannitol applied with 
virus treatment  
A: LV only control; B: 5% w/v mannitol; C: 12.5% w/v; D: 15% w/v; E: 20% w/v; F: 25% w/v. Scale bar 




The number of cells transduced per frame was counted using ImageJ and averaged. 
The average number of cells transduced per frame when co-administered with each 
concentration of mannitol is shown in the graph below.  
 
Figure 3.32 – graph showing average number of cells transduced when different concentrations 
of mannitol are co-administered with LV  
Error bars indicate standard deviation.  
 
The average number of cells transduced did not show any difference following 
treatment with various mannitol concentrations (Figure 3.32).  
For the sequential administration, 30 μL of each concentration of mannitol was added 
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Figure 3.33 – LV transduced HT1080 cells at different concentrations of mannitol applied prior 
to virus treatment  
A: LV only control; B: 5% w/v mannitol; C: 12.5% w/v; D: 15% w/v; E: 20% w/v; F: 25% w/v. Scale bar 
200 μm  
 
The average number of cells transduced per frame when co-administered with each 




Figure 3.34 – graph showing average number of cells transduced when different concentrations 
of mannitol are administered prior to LV  
Error bars indicate standard deviation.  
 
There is no significant effect of mannitol concentration on the number of cells 
transduced when administered sequentially (Figure 3.34; as was done during the 
stereotaxic surgeries).  
 
3.9 Cloning  
3.9.1 PCR amplification of T2A-mCherry insert  
PCR amplification of the T2A-mCherry sequence with In-Fusion® primers produce an 
813 bp fragment. Five microlitre of each PCR reactions was electrophoresed on a 1% 
agarose gel and stained with ethidium bromide to visualise DNA. The gel image 
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Figure 3.35 – Amplification of T2A-mCherry insert using In-Fusion® primers  
T2A-mCherry PCR product from using In-Fusion® primers with different starting amounts of plasmid 
DNA carried out in duplicates. All PCR runs returned positive with a band just under 850 bp (against 
the ladder), which matches the expected fragment size of 813 bp. The no primer control did not produce 
a band.  
 
All PCR runs returned positive with band on the gel of the expected amplicon size, just 
under 850 bp according to the DNA ladder. The remainder of the PCR products were 
purified before running out on a gel for gel excision and purification of only the required 
fragment size. The gel of purified PCR products was visualised with UV light for 
excision of the gel fragment containing the PCR product; it was imaged post-excision 
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Figure 3.36 – Gel image post-excision of PCR products for gel purification  
Gel image taken after excision of gel fragments containing PCR products (derived from starting amounts 
of 30, 50 and 100 ng of plasmid DNA) at around the 850 bp size for gel purification.  
 
Nanodrop results of the gel purified PCR products came back with low yield and poor 
A260/A280 ratios which indicated poor purity of DNA. It was decided to proceed with 
the In-Fusion® cloning reaction using the purified PCR product from the 300 ng of 
starting plasmid DNA which had a 260/280 ratio of 1.98 and DNA yield of 51.1 ng/μL.  
 
3.9.2 Restriction digest of vector plasmid  
The vector plasmid was linearised using the restriction enzyme SalI. The restriction 
digest was electrophoresed on a 1% agarose gel (against an uncut vector) and stained 
with ethidium bromide. This enabled the verification of the digested plasmid size; being 
the same as the uncut. It also allowed for gel purification of the digested product.  




The resulting image (Figure 3.37) shows that the digested plasmid was the same size 
as the uncut, approximately 9000 bp.  
 
Figure 3.37 – Gel image showing restriction digested and undigested vector plasmid 
(left – right) SalI digested and undigested vector plasmids are of the same size; streaking may be due 
to overloading of DNA sample into wells.  
 
3.9.3 In-Fusion® reaction and transformation of competent cells  
The SalI digested vector plasmid was used to carry out the In-Fusion® cloning protocol 
with the purified PCR product. Following the cloning protocol, Stbl3 competent E.coli 
cells were transformed with the cloning reaction and both positive and negative In-
Fusion controls. LB agar are inoculated with transformed cells. The positive and 





negative In-Fusion® controls produced expected results; with the positive control 
producing too many colonies to count, while the negative control had less than 10 
colonies on the plate.  
 
3.9.4 Screening for positive colonies  
Colonies from the plate of In-Fusion® cloned plasmid were picked and inoculated onto 
a strike plate and used for colony PCR. Eight colonies from the plate of transformants 
were chosen for colony PCR using the selected primers (2.3.1). The In-Fusion cloning 
reaction was also screened with the colony PCR primers to verify that the cloning 
reaction was successful. Successful In-Fusion cloning will allow amplification through 
both primers which would produce a 213 bp fragment.  
Colony PCR products from all 8 colonies and the In-Fusion® cloning reaction were 





Figure 3.38 – Gel image of colony PCR results  
Successful colony PCR would produce an approximately 200 bp fragment. The In-fusion cloning 
reaction has a clear band of the right size; indicating that the cloning was successful. Colonies 2 to 8 
show signs of being positive of successful In-Fusion cloning.  
 
3.9.5 Sequencing and alignment  
Colony 2 and 3 were selected and mini-prepped for DNA isolation, to be sent for 
sequencing as verification of successful cloning. The returned sequences were 
uploaded onto Geneious and aligned with the expected pCDH-pSyn-SP-GFP-sAPPα-
T2A-mCherry plasmid. The sequence alignment (Figure 3.39) for colony 2 indicated 
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Figure 3.39 – Alignment of sequencing results against expected plasmid  
Sequencing results from GAS for colony 2 aligned against the sequence for pCDH-pSyn-SP-GFP-
sAPPα-T2A-mCherry; green peaks show 100% consensus in alignment, which is observed through the 
majority of the good quality sequencing result of colony 2.  
 
The glycerol stock of colony 2 was then used to midi-prep for higher yield DNA isolation 
to be used in virus packaging.  
 
3.10 Virus production  
3.10.1 Testing in primary neurons by immunocytochemistry  
Upon completion of lentiviral packaging and production, the LV-pCDH-pSyn-SP-GFP-
sAPPα-T2A-mCherry was tested in vitro on primary neurons. Two volumes (0.5 μL 
and 2 μL) of virus was administered and allowed to incubate overnight before fixing 
and ICC was carried out with anti-GFP.  







Figure 3.40 – Primary neurons show co-localisation of GFP and mCherry from 0.5 μL of LV 
transduction  
A-B: one frame of cells showing GFP and mCherry (respectively); C: overlay of A and B.  
D-E: second frame of cells showing the same respective reporter genes; F: overlay of D and E.  
C and F shows co-localisation of GFP and mCherry, indicating successful expression by the viral 
construct with GFP-sAPPα and mCherry. Scale bar 200 μm.  
 
A second volume, increased to 2 μL, was also tested to examine if it would improve 





Figure 3.41 – Primary neurons show co-localisation of GFP and mCherry from 2 μL of LV 
transduction  
A-B: one frame of cells showing GFP and mCherry (respectively); C: overlay of A and B.  
D-E: second frame of cells showing the same respective reporter genes; F: overlay of D and E.  
C and F shows co-localisation of GFP and mCherry, indicating successful expression by the viral 
construct with GFP-sAPPα and mCherry. Scale bar 200 μm.  
 
The increased volume delivered (Figure 3.41) did not have a significant effect on the 
transduction efficiency of the virus (Figure 3.40); mCherry was still well-expressed and 
clearly localised to cells but GFP expression was still weak and had to be enhanced 
by ICC to be easily observed.  
 
3.11 Spread of sAPPa from lentivirus-mediated transduced cells in the brain  
It was decided to use the LV-pCDH-pSyn-SP-GFP-sAPPα-T2A-mCherry in vivo and 




Figure 3.42 – Detected fluorescence in LV-pCDH-pSyn-SP-GFP-sAPPα-T2A-mCherry injected 
mouse brain  
A: Anti-GFP stained section with some visualised fluorescence; B: possible mCherry reporter gene 
expression; C: fluorescence co-localises  
 
All four animals injected with this virus failed to show any sign of fluorescence; of either 
GFP or mCherry. Even with anti-GFP IHC carried out on tissue sections, fluorescence 
was only observed in the section shown in Figure 3.42 which suggests unsuccessful 
viral expression, and potentially a combination of auto-fluorescence and non-specific 






Chapter 4: Discussion  
4.1 Summary  
The primary aim of this study was successfully achieved; viral vector spread between 
the AAV9 vector and rabies B19 pseudotyped LV vector was compared. AAV9 was 
found to be able to achieve significantly more widespread distribution compared to the 
LV. Distance of spread achieved by undiluted AAV9, a 1:10 diluted titre of AAV9 and 
AAV with mannitol pre-treatment was not significantly different.  
LV with mannitol pre-treatment was unsuccessful as no GFP expression was 
observable.  
The pCDH-pSyn-SP-GFP-sAPPα-T2A-mCherry plasmid was packaged into a LV 
construct and tested successfully in vitro on primary neurons. In vivo use of the virus 
did not express either reporter genes.  
 
4.2 Viral vector transduction efficiency  
4.2.1 LV vs. AAV9  
LV mediated transduction was shown to be localised to the immediate region of the 
injection. Distance of spread was approximately a millimetre either side (anterior-
posterior) of the injection site. Retrograde transport to distal regions such as the 
entorhinal or association cortices was not observed. Retrograde transport to the 
subiculum in some mice hippocampi were faintly observable.  
At the undiluted higher titre of AAV9, GFP expression was widespread and observed 
through the length of the entire brain; 1 cm of spread from cerebellum to the olfactory 
nuclei. Such a high level of GFP expression throughout each section meant that if any 
effect of mannitol pre-treatment were to be observed, a lower ‘baseline’ for an AAV9 
spread would be required. Therefore, it was decided that another set of injections 
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would be carried out with a 1:10 diluted AAV9 titre so as to provide a comparable 
baseline for the mannitol pre-treatment.  
The highly widespread distribution of the AAV9 vectors was noteworthy as a single 
unilateral injection at a higher viral titre was able to achieve transduction of a significant 
proportion of the cerebral volume. When using a LV vector, this was only possible with 
multiple injection sites in both hemispheres of the brain (as was done by NDD lab 
members; Fairuz Yahya and Valerie Tan, in unpublished PhD research). Their work 
used lentiviral mediated introduction and over-expression of sAPPα to either prevent 
or rescue the effects in transgenic AD mice. The studies have used a LV vector to 
deliver sAPPα with a separate GFP molecule to tag transduced cells. The APP/PSEN1 
double mutant tg mice (1.2.2) were used. A total of 4 injections at 2 depths each (8 
sites in total) into both the left and right hippocampus were used to achieve high level 
of transgene expression. LV administration was carried on groups of mice before and 
after AD-like symptoms develop to determine if sAPPα could prevent and/or rescue 
AD-like pathology.  
The 1:10 diluted AAV9 injections performed just as well in terms of distance of spread. 
When area of fluorescence was quantified, the distribution of GFP expression was 
shown to have a very slightly narrower peak than that of the undiluted AAV9 group. It 
was also visually observable that fewer cells had been transduced, due to the 
presence of fewer viral particles in the same volume.  
Furthermore, another aspect in which the AAV9 vectors outperformed the LV was the 
distal regions and structures that were GFP expressing from retrograde transport. 
Regions such as the entorhinal and association cortices were shown to be strongly 
transduced; the ability of the AAV9 vector to produce retrograde spread to these 
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structures both validates the suitability of AAV9 as a gene therapy vector in the CNS 
and the CA1 region as a good target for AD and other cognitive diseases.  
Furthermore, the distance of GFP expression spread with AAV9 was shown to be 
approximately 1 cm, however that was only examining expression with in the brain. All 
AAV9 transduced brains showed signs of the pyramidal tract being strongly GFP 
expressing in the medulla (the spread of transgene expression is reliant on transport 
along neuronal projections and processes and so, a one centimetre spread in the 
mouse brain is translated to a relatively greater distance in the human CNS). The 
pyramidal tract conducts motor neurons and impulses from the brain to the spinal cord; 
this means that it was likely that AAV9 mediated transduction extends to farther 
regions of the CNS (spinal cords of all AAV9 injected mice were fixed and stored; and 
this may be confirmed in future).  
AAV9 had already been shown to efficiently transduce CNS cells (Dayton et al., 2012) 
through other routes of administration, such as intravenous and systemic delivery 
(Manfredsson et al., 2009) but they did not achieve widespread transduction of the 
CNS through non-intracranial routes. This has implications for CNS diseases such as 
motor neuron disorders which will require widespread delivery of therapeutics 
throughout the CNS.  
Reducing injection sites by having a viral vector with a much greater transduction 
efficiency would also improve behavioural tests conducted on affected animals 
delivered with a therapeutic. Especially when targeting the hippocampus which is the 
primary area of interest in AD and responsible for memory and learning. Multiple 
injections into the hippocampus to deliver a therapeutic transgene carrying viral vector 
may achieve the desired spread and delivery of the therapeutic, however, it would 
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serve little purpose if the trauma from multiple descending needles had damaged the 
hippocampus significantly to render results from behavioural studies unusable.  
However, while not achieving the same level of transduction efficiency as the AAV9 
vector, LV can still be used to deliver therapeutics within the CNS for disorders with 
localised affected neurocircuitry, such as targeting of the substantia nigra for treating 
Parkinson’s Disease (Fearnley & Lees, 1991).  
This is relevant in terms of translating viral vector mediated gene therapy for human 
use in the future; where vector choice and administration routes into a patient would 
determine the safety and desirability of such a procedure.  
 
4.2.2 Effect of 25% w/v mannitol  
LV injections of mice, pre-treated with mannitol, failed to produce any GFP expression. 
The effect of mannitol on LV titre, and resulting transduction efficiency was tested in 
vitro. However, neither simultaneous nor sequential addition of mannitol followed by 
LV (mimicking the process in vivo), produced any significant changes to the number 
of transduced cells expressing GFP.  
Diluted AAV9 with mannitol pre-treatment resulted in significantly improved distance 
of spread compared to LV; but not significantly different from either undiluted or diluted 
AAV9, which ruled out a mannitol effect on improved AAV9 versus LV spread.  
However, of note in the AAV9 with mannitol pre-treatment, was the lack of 
hippocampal expression of GFP. There were a few possible reasons; firstly human 
error (misidentifying bregma, misreading the stereotaxic frame coordinates, mistake 
in reading dorsal-ventral depth coordinates etc) during surgery resulting in either a 
shallow injection site or missing the hippocampus entirely. It seemed unlikely that it 
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would happen in four consecutive animals, especially after numerous successful 
surgeries on previous occasions. Furthermore, apart from the absence of GFP within 
the hippocampus, the pattern of expression closely matches that of the diluted AAV9 
group; this suggests that distal expression of GFP arose from retrograde spread from 
a CA1 hippocampal administration of AAV9.  
It is possible that both mannitol and AAV9 introduced together in mice might trigger an 
immune response which localised to the area of trauma (ie. injection site), preventing 
transgene expression and/or accumulation within the region.  
 
4.2.3 Future use of mannitol with viral vectors  
Mannitol as an osmotic agent is still useful as a means of opening intercellular space 
for dispersal of transport of therapeutics to and from an area. It might be worth 
considering administering mannitol after viral injection; this would give time for 
expression of the transgene and in the case of sAPPα, secretion into the extracellular 
space. Mannitol administration at this point would allow specific spread and dispersal 
of any secreted therapeutic. This would allow for much more specific targeting of 
transgene expression (especially if combined with using cell-specific promoters) with 
subsequent dispersal of the therapeutic.  
Furthermore, it was recently reported that transient opening of tight junctions and the 
blood-brain barrier (similar actions of mannitol) with scanning ultrasound allowed 
recruitment of macrophages which reduced plaque formation and improved memory 




4.2.4 Visualising sAPPα in vivo  
Unfortunately despite producing a working plasmid and virus which showed 
expression of both reporter (mCherry and GFP) genes in vitro, transgene expression 
was not visible in vivo across any of the four animals.  
There may have been insufficient time for sAPPα to express and/or accumulate (if 
sAPPα accumulates at all) to be visualised. sAPPα may have a short half-life, or its 
function involves a rapid turnover of the molecule.  
However, none of these reasons explain the absence of mCherry in the brains; 
mCherry was very strongly expressed when testing the virus in primary neurons after 
a 24 hour incubation period.  
 
4.3 Limitations of techniques  
4.3.1 Analysis of brain tissue  
Fluorescence microscopy of the sections provided a simple way of visualising reporter 
gene expression however because only every sixth section was being imaged, it does 
mean that a large proportion of the transduction distribution is simply extrapolated from 
the imaged sections. Three-dimensional imaging may provide a better (or overall time-
saving) method to visualise structures in the brain, especially fluorescently labelled 
cells. A method known as “clear lipid-exchanged, acrylamide-hybridised rigid, 
imaging/immunostaining tissue hydrogel” (CLARITY; Chung & Deisseroth, 2013), 
which replaces the lipids of the brain with a clear acrylamide to enable visualisation of 
proteins and structures of the brain while fixed ‘in situ’. The actual method of 
conducting CLARITY is not the biggest challenge; rather finding an adequate and cost-
effective 3D imaging platform.  
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Another method of imaging, confocal microscopy would have to be carried out, in 
future, especially on IHC stained sections to improve visualisation of co-localisation of 
differentially labelled cells.  
 
4.3.2 Statistical analysis  
A direct comparison was not made with each treatment group due to personal 
limitations with the statistical program RStudio. The statistical code used for scaling 
and presenting the data was written in full by Dr Michael Black. However the data 
gathered had off-target injections which skewed certain plots, namely the mean 
trendline for the LV treatment group.  
Improvements to the data analysis could be carried out with the area of fluorescence 
regrouped against the largest area (expected injection site) as the ‘zeroed’ coordinate 
(instead of against bregma; to account for off-target injections) to produce the 
trendline.  
 
4.4 Conclusion and Future directions  
This project has shown the marked improvement in transduction efficiency from using 
AAV9 vector to deliver a reporter gene. It efficiently achieves widespread transduction 
of the CNS from a unilateral injection at the hippocampus. However, AAV has a limited 
transgene capacity (4-5 kb), about half that of LV vectors. However, while LV has a 
limited spread, it would be useful for targeted delivery of treatment.  
At the moment, AD research in the NDD lab is looking to utilise AAV9 as a vector to 
deliver truncated regions of the sAPPα peptides which retain the neuroprotective 
properties of the full-length protein.  
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While mannitol did not have any observable positive effect, future attempts can be 
made to determine if it does have a definitive negative effect on viral vectors; or 
utilising timepoints post-injection to administer the mannitol for improving secreted 
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Appendix A: Details of treatment groups in chronological order  
 
Group ID  Animal no. Animal ID Vector  Duration  
1_30Apr  3  5081  LV  7 days  
5082  LV  31 days  
5083  No virus control  7 days  
2_5Jul  3  IC001 – IC003  LV  14 days  
3_8Jul  3  IC004 – IC006  LV  28 days  
4_12Dec  3  IC007 – IC009  5% w/v dextran (MW 10,000)  O/N  
5_Jan  4  IC010 – IC013  LV  28 days  
5.1_Jan  4  IC014 – IC017  AAV9  28 days  
6_AWO  1 IC018  5% w/v dextran (MW 10,000)  O/N  
7_May  4  IC019 – IC022  LV +/mannitol  28 days  
7.1_May  4  IC023 – IC026  1:10 AAV9 +/mannitol  28 days  
8_July  4  IC027 – IC030  LV  28 days  
8.1_July  4  IC031 – IC034  1:10 AAV9  28 days  






Appendix B: RVM drug concentrations and administration dosage  
 
Drug Dose rate Concentration Vol. to weight Supplier  
     
Ketamine 40 mg/kg 10 mg/ml 4μL/g  Parnell Laboratories NZ Ltd.  
Domitor 0.25 mg/kg 0.1 mg/ml 2.5μL/g  Novartis NZ Ltd.  
Atropine 0.05 mg/kg 0.0065 mg/ml 7.7μL/g  Baxter Healthcare Ltd.  
KDA    14.2μL/g   
     
Lopaine 4 mg/kg 0.5 mg/ml 8μL/g  Ethical Agents Ltd.  
Norocarp 5 mg/kg 1 mg/ml 5μL/g  Norbrook NZ Ltd.  






Appendix C: ImageJ functions used  
Area of fluorescence processes  
Open image  
Image > Type > 8-bit >  
Edit > Invert >  
Image > Adjust > Threshold [settings: adjust visually; exclude on edge]  
 
ImageJ – cell counting  
Open image  
Process > subtract background [settings: 50.0 pixels; no selection]  
Image > adjust > threshold [settings: B&W; adjust as required]  
Image > type > 8-bit  
Process > binary > fill holes  
Process > binary > convert to mask  
Process > binary > watershed  







Appendix D: Solutions and Buffers  
 
Solutions for Gel Electrophoresis 
25x TAE Buffer 
800 mL dH2O 
57.1 mL Glacial acetic acid 
100 mL EDTA 0.5 M 
242 g Tris 
Mix and make up to 1000 mL with dH2O 
1x TAE Buffer 
40 mL TAE buffer 25x 
960 mL dH2O 
1% Agarose 
3g Agarose Ultra-Pure Powder 
300 mL TAE 1x 
Microwave to dissolve agarose 
5 μL of ethidium bromide to every 50 mL of agarose per gel casting  
 
Solutions for tissue fixing and mounting  
4% Paraformaldehyde 
40 g paraformaldehyde (PFA) 
500 mL 0.1 M PB 
Stir and warm to 60°C until the PFA has dissolved 
Fill to 1 L with 0.1 M PB 




0.1M PB  
Solution A 
27.6 g sodium phosphate monobasic (NaH2PO4H2O) 
Add 1 L dH2O 
Solution B 
53.56 g sodium phosphate dibasic (Na2HPO47H2O) 
Add 1 L dH2O 
Mix 280 mL of solution A with 720 mL of solution B 
Dilute with dH2O to a volume of 2 L 
pH to 7.2 by adding more solution A or solution B 
Cryoprotectant  
400 mL 0.1M PB 
 300 g Sucrose  
 300 mL Ethylene glycol  
Anitfade  
 20 mL of 0.1M PB  
1.1 g of p-phenylenediamine dihydrochloride (PPD)  
80 mL glycerol  
 
Solutions for Immunolabelling  
1x PBS  
 1 L 0.1M PB  
127 
 
 9 g of sodium chloride (NaCl) 
 1x PBS + 0.2% Triton  
 500 mL of 1x PBS  
 1 mL of Triton X-100  
Blocking solution  
 97 mL of 1x PBS-T + 0.2% Triton  
 3 mL of normal goat serum (NGS)  
Primary or secondary antibody  
 X μL of primary antibody (depending on concentration required)  
 Make up to 1 mL with blocking solution  
 
 
